BG107078A - Pyrrole-substituted 2-indolinone protein kinase inhibitors - Google Patents
Pyrrole-substituted 2-indolinone protein kinase inhibitors Download PDFInfo
- Publication number
- BG107078A BG107078A BG107078A BG10707802A BG107078A BG 107078 A BG107078 A BG 107078A BG 107078 A BG107078 A BG 107078A BG 10707802 A BG10707802 A BG 10707802A BG 107078 A BG107078 A BG 107078A
- Authority
- BG
- Bulgaria
- Prior art keywords
- mixture
- amount
- toluene
- soft block
- composition according
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Abstract
Description
I. ОБЛАСТ НА ТЕХНИКАТАI. TECHNICAL FIELD
Полезният модел се отнася до полиуретанов състав за мека блокова пяна, който ще намери приложение в мебелната промишленост и бита.The utility model relates to a polyurethane composition for soft block foam that will find application in the furniture and household industries.
• · · · ·· ···· • ·• · · · · · · · · ·
П. ПРЕДШЕСТВУВАЩО СЪСТОЯНИЕ НА ТЕХНИКАТАP. BACKGROUND OF THE INVENTION
Известно е от /1/ полиуретанов състав на полиестерна блокова пяна съдържаща органичен полиизоцианат , полиестер полиол, уретанов катализатор, вода като разпенващ агент и специален силиконов стабилизатор.It is known from (1) polyurethane composition of polyester block foam containing organic polyisocyanate, polyester polyol, urethane catalyst, water as foaming agent and special silicone stabilizer.
Ш. ТЕХНИЧЕСКА СЪЩНОСТ НА ПОЛЕЗНИЯ МОДЕЛW. TECHNICAL NATURE OF THE USEFUL MODEL
Полиуретановят състав съгласно полезния модел е на мека блокова пяна съдържаща пеностабилизатор, който е в количество / тегл.ч./ от 0.5 до 1.5 и е модифицирани полиетерни полисилоксани и тензиди и/или полиалкиленоксидиметилсилоксан съполимер-хексиленгликол и/или натриевдодецилбензилсулфонат и етоксилиран нонилфенол и 1,2етандиол моноетиленгликол и катализатор в количество от 0.2 до 2 и е смес от бис(2-диметиламиноетил)етер и нейонно повърхносттно активно вещество и 1,4-диметилпиперазин или смес 1,4-диметилпиперазин и бис(2-диметиламиноетил)етер или смес 1,4-диметилпиперазин и нонилфенол етоксилиран или смес от амини и полиетермодифицирани силоксани и повърхностно активни вещества или Νметилморфолин. Останалите компоненти на състава по полезния модел са в следните количества полиестерни полиоли- 100, изоцианат в количество от 25 до 65 и е ,толуилен-2,4-диизоцианат и толуилен-2,6-диизоцианат които са в съотношение 80:20 и/или толуилен-2,4-диизоцианат и толуилен2,6-диизоцианат в съотношение 65:35 или смес от тях,разпенващ агент вода в количество от 1,2 до 6.Съгласно варианти на изпълнение на състава по полезния модел, той допълнително съдържа в даден случай пигменти в количество от 0.1 до 10 и/или антиоксиданти в количество от 0.4 до 0.6 и в даден случай пламъкозабавители в количество от 2 до 40 или в даден случай пълнител в количество от 3 до 50 или в даден случай диамид на ·· ··♦· • · • · • ♦ · · • · · · ·· • · · · ·* • · · · · ·· • · · · · ··The polyurethane composition according to the utility model is a soft block foam containing a foam stabilizer, which is in an amount (wt) of from 0.5 to 1.5 and is modified polyether polysiloxanes and surfactants and / or polyalkyleneoxydimethylsiloxane copolymer-hexylene glycol and / or natilenebenzylethenylbenzene , 2 ethanediol monoethylene glycol and a catalyst in an amount of 0.2 to 2 and is a mixture of bis (2-dimethylaminoethyl) ether and a non-ionic surfactant and 1,4-dimethylpiperazine or a mixture of 1,4-dimethylpiperazine and bis (2-dimethylaminoethyl) ether or a mixture of 1,4-dimethylpiperazine and nonylphenol ethoxylated, or a mixture of amines and polyether-modified siloxanes and surfactants or лmethylmorpholine. The other components of the composition of the utility model are in the following amounts of polyester polyols-100, isocyanate in an amount of 25 to 65 and e, toluene-2,4-diisocyanate and toluene-2,6-diisocyanate which are in the ratio 80:20 and / or toluene-2,4-diisocyanate and toluene2,6-diisocyanate in a ratio of 65:35 or a mixture thereof, blowing agent water in an amount of from 1.2 to 6. According to embodiments of the composition according to the utility model, it further contains in optionally pigments in an amount of 0.1 to 10 and / or antioxidants in an amount of 0.4 to 0.6 and optionally flames abductors in an amount of from 2 to 40 or optionally a filler in an amount of from 3 to 50 or optionally a diamide of · · · · · · · · · · · · · • · · · · · · · · · · · ·
...········ въглеродната киселина /карбамид/ в количество от 0.2 до 1 и силиконово масло в количество от 0.01 до 0.05 или в даден случай алкилсулфонкиселинен естер на фенола/ мезамол / в количество от 0.5 до 5 и триглицерид на стеариновата киселина /стеарин/ в количество от 0.005 до 0.1.... · carbon dioxide (urea) in an amount of 0.2 to 1 and silicone oil in an amount of 0.01 to 0.05 or optionally an alkyl sulfonic acid ester of phenol / mesamol / in an amount of 0.5 to 5 and triglyceride of stearic acid (stearin) in an amount of 0.005 to 0.1.
Съгласно полезния модел полиестерните полиоли са разклонени алифатни полиестерни полиоли с хидроксилни групи на база диол, триол иAccording to a useful model, polyester polyols are branched aliphatic polyester polyols with hydroxyl groups based on diol, triol and
адипинова киселина.adipic acid.
Сместа от ,толуилен-2,4-Диизоцианат и толуилен-2,6-диизоцианат 80:20 и толуилен-2,4-диизоцианат и толуилен-2,6-диизоцианат 65:35 е в съотношение от 1.:1,5 до 4:1.The mixture of toluene-2,4-diisocyanate and toluene-2,6-diisocyanate 80:20 and toluene-2,4-diisocyanate and toluene-2,6-diisocyanate 65:35 is in the ratio of 1.:1,5 up to 4: 1.
Съгласно полезния модел пеностабилизатора съдържа следните количества / тегл.ч./ от полиалкиленоксидиметилсилоксан съполимер 80 и хексиленгликол 20 и/или натриевдодецилбензилсулфонат 15 и етоксилиран нонилфенол 40 и 1,2-етандиол моноетиленгликол 45.According to a useful model, the foam stabilizer contains the following amounts (parts by weight) of polyalkyleneoxydimethylsiloxane copolymer 80 and hexylene glycol 20 and / or sodium dodecylbenzylsulfonate 15 and ethoxylated nonylphenol 40 and 1,2-ethanediol monoethylene glycol 45.
Използваният катализатор по полезния модел е смес в съотношение от 1:1 до 1: 4 от следните количества на бис(2-диметиламиноетил)етер от 20 до 60 с нейонно повърхностгно активно вещество от 20 до 50 и 1,4диметилпиперазин или е смес на 1,4-Диметилпиперазин от 20 до 25 и бис(2-диметиламиноетил)етер от 15 до 20 или е смес на 1,4диметилпиперазин 32 и нонилфенол етоксилиран 40.The utility catalyst used is a 1: 1 to 1: 4 ratio of the following amounts of bis (2-dimethylaminoethyl) ether 20 to 60 with a non-ionic surfactant 20 to 50 and 1,4 dimethylpiperazine, or a mixture of 1 , 4-Dimethylpiperazine 20 to 25 and bis (2-dimethylaminoethyl) ether 15 to 20 or a mixture of 1,4dimethylpiperazine 32 and nonylphenol ethoxylated 40.
Полезният модел предлага вариант на изпълнение в който състава допълнително съдържа пламъкозабавители които са трис(1,3дихлоризопропил)фосфат и/или смес от олигомерни хлоретилфосфати, и/или халогенирани арил естери и/или 2,4,6,- триамино= 1,3,5триазин, цианурамид.The utility model provides an embodiment in which the composition further comprises flame retardants which are tris (1,3dichloroisopropyl) phosphate and / or a mixture of oligomeric chloroethyl phosphates and / or halogenated aryl esters and / or 2,4,6, - triamino = 1,3 , 5triazine, cyanuramide.
Използваният съгласно вариант на изпълнение на полезния модел пълнител е микронизиран калциев карбонат с размер на частиците 2,5 μ, повърхностно обработен или необработен или поливинилхлорид с размер на частиците 60 μ.The filler used in the embodiment of the utility model is micronized calcium carbonate with a particle size of 2.5 μ, surface treated or untreated or polyvinyl chloride with a particle size of 60 μ.
Съгласно полезния модел антиоксидант е смес от следните компоненти в количество /тегл.ч./ децил дифенил фосфат от 25 до 50 и бензоатен дериват от 25 до 50 и фенолен дериват от 25 до 50.According to a useful model, an antioxidant is a mixture of the following components in an amount of / parts by weight / decyl diphenyl phosphate from 25 to 50 and a benzoate derivative from 25 to 50 and a phenolic derivative from 25 to 50.
Съгласно друг вариант на изпълнение на полезния модел пигментите са полимерна пигментна смес или дисперсни пигменти.According to another embodiment of the utility model, the pigments are a polymer pigment mixture or dispersed pigments.
Производството на състава съгласно полезния модел се осъществява на разпенваща инсталация тип “високо налягане”, по непрекъснат метод, чрез смесване на дозирани количества полиестерен полиол, изоцианат или смес от изоцианати, вода като разпенващ агент, силиконов пеностабилизатор, аминокатализатор или смес от аминокатализатори .Съгласно вариантите на изпълнение на полезния модел и в зависимост от изискванията към крайния продукт допълнително състава съдържа пламъкозабавител или смес от пламъкозабавители, пълнители, пигменти, антиоксидант и други добавки.Смесването се осъществява в осцилираща смесителна камера, върху движеща се транспортна лента, при непрекъснат компютърен контрол. След разпенване на течната смес от компонентите и омрежване, се оформя полиуретанов / ПУ/ блок с непрекъсната дължина и правоъгълно напречно сечение, който се реже и след 24-часово съхранение за окончателно омрежване, се конфекционира на специализирани машини до зададени размери. Съгласно полиуретановия състав по полезния модел предпочитано се използват продуктите на фирмите Bayer AG, BASF,DOW,AIR PRODUCTS,Witco SA,Goldschmidt AG, AKZO.Production of the composition according to the utility model is carried out on a high-pressure foam installation, by continuous method, by mixing metered quantities of polyester polyol, isocyanate or a mixture of isocyanates, water as a blowing agent, silicone foam stabilizer, aminocatalyst or mixture of amino acids. the embodiments of the utility model and, depending on the requirements for the final product, the composition further comprises a flame retardant or a mixture of flame retardants, fillers, pigments, antioxidants Idan and other dobavki.Smesvaneto is carried out in an oscillating mixing chamber on a moving conveyor belt in a continuous computer control. After foaming of the liquid mixture of components and crosslinking, a continuous length polyurethane / PU / block is formed, and a rectangular cross section is cut, and after 24 hours of storage for final crosslinking, it is made up to specialized machines to specified sizes. According to the polyurethane composition of the utility model, the products of the companies Bayer AG, BASF, DOW, AIR PRODUCTS, Witco SA, Goldschmidt AG, AKZO are preferably used.
Съставът по полезния модел има следните предимства осигурява широк диапазон от плътност и твърдост при натиск за 40% деформация, в съчетание с високи якостни показатели - якост на опън и относително удължение при скъсване.The composition of the utility model has the following advantages provides a wide range of density and compressive strength for 40% deformation, combined with high strength characteristics - tensile strength and relative tear elongation.
Съставът осигулява равномерна, фина клетъчна структура, подходяща за каширане по пламъченн метод с тъкани и нетъкани текстили, трика, изкуствена кожа и пластмасови фолиа и съгласно вариант на изпълнение на полезния модел и трудногорими качества.The composition provides a uniform, fine cellular structure, suitable for flame lining with woven and non-woven fabrics, gimmicks, imitation leather and plastic foils and in accordance with the utility model and flame-retardant embodiment.
Съгласно вариант на изпълнение на състава по полезния модел ПУ пяна, естерен тип е и с неравномерна, едропореста структура, наподобяваща морска пяна, вAccording to a variant embodiment of the composition according to the utility model PU foam, the ester type is also with a non-uniform, large porous structure, resembling sea foam, in
широка гама устойчиви,wide range of resistant,
наситени цветове разнообразни размери и форми, подходяща за гъби за баня и изделия за бита.saturated colors in various sizes and shapes, suitable for bath sponges and household products.
Друг вариант на изпълнение на състава осигурява ПУ пяна с равномерна, груба, едропореста структура подходяща за гъби с абразивно действие за промишлени цели и за бита.Another embodiment of the composition provides PU foam with a uniform, coarse, porous structure suitable for abrasives with industrial and household abrasives.
IV. ПРИМЕРНО ИЗПЪЛНЕНИЕ НА ПОЛЕЗНИЯ МОДЕЛIV. EXAMPLE IMPLEMENTATION OF THE USEFUL MODEL
Пример 1: Съставът по примера съдържа/ в Kg/:Example 1: The example composition contains (in Kg):
100,00 - полиестерполиол с хидроксилно число 60100.00 - polyester polyol with hydroxyl number 60
43,00 - смес 3:1 от 2,4 и 2,6 толуилендиизоцианат в съотношение 80:20 и43.00 - a mixture of 3: 1 of 2,4 and 2,6 toluylenediisocyanate in the ratio 80:20 and
2,4 и 2,6 толуилендиизоцианат в съотношение 65:352,4 and 2,6 toluylenediisocyanate at 65:35
3,6 - вода3.6 - water
0,85 - смес от модифицирани полиетерни полисилоксани и тензиди0.85 - a mixture of modified polyether polysiloxanes and surfactants
1,35 - смес от 32%-1,4 диметилпиперазин и 40%нонилфенол етоксилиран1.35 - mixture of 32% -1,4 dimethylpiperazine and 40% nonylphenol ethoxylated
0,50 - дисперсен пигмент0.50 - dispersed pigment
Технологията включва следната последователност от операции на разпенваща инсталация тип “високо налягане”: дозиране на полиестерен полиол, изоцианати, вода, силиконов пеностабилизатор, аминокатализатори и пигменти в количества, съобразно рецептурата при непрекъснат компютърен контрол на всички дебити в границите на зададените отклонения и контрол на температурата в граници 25 ± 5^2, хомогенизиране в осцилиращата със скорост 10-50 м./мин. смесителна камера и изливане на течната смес от компоненти върху непрекъкнато движеща се транспортна лента при скорост 2-10 м./мин и наклон 0,5-5°. След разпенване и омрежване, се оформя ПУ блок с непрекъсната дължина и правоъгълно напречно сечение, който се реже и след 24-часово съхранение за окончателно омрежване, се конфекционира на специализирани машини до зададени размери. Съставът по примера е на естерна, мека, блокова ПУ пяна, която е с плътност 30 kg/m3 по DIN 53420 • · · · · ·The technology includes the following sequence of operations of a high-pressure foam installation: dosing of polyester polyol, isocyanates, water, silicone foam stabilizer, aminocatalysts and pigments in quantities according to the recipe for continuous computer control of all flow rates within the set deviations and control temperature in the range 25 ± 5 ^ 2, homogenization in the oscillating at a speed of 10-50 m / min. mixing chamber and pouring the liquid mixture of components onto a continuously moving conveyor belt at a speed of 2-10 m / min and a slope of 0.5-5 °. After foaming and cross-linking, a continuous-length PU block with a rectangular cross-section is formed, which is cut and after 24-hour storage for final cross-linking, is specialized in specialized machines to the specified sizes. The composition of the example is an ester, soft, block PU foam having a density of 30 kg / m 3 according to DIN 53420.
·· · ·· и твърдост 4,0 kPa по DIN 53577, подходяща за каширане с текстили по пламъчен метод,· · · · And a hardness of 4.0 kPa according to DIN 53577, suitable for flame lining of textiles,
Пример 2. Съставът по примера съдържа:Example 2. The composition of the example contains:
100,00 - полиестерполиол с хидроксилно число 60100.00 - polyester polyol with hydroxyl number 60
44.10 - смес 2:1 от 2,4 и 2,6 толуилендиизоцианат в съотношение 80:20 и44.10 - a mixture of 2: 1 of 2,4 and 2,6 toluylenediisocyanate in the ratio 80:20 and
2,4 и 2,6 толуилендиизоцианат в съотношение 65:352,4 and 2,6 toluylenediisocyanate at 65:35
3,6 - вода3.6 - water
0,85 - смес от модифицирани полиетерни полисилоксани и тензиди0.85 - a mixture of modified polyether polysiloxanes and surfactants
1,35 - смес от 32%-1,4 диметилпиперазин 32% и 40%нонилфенол, етоксилиран1,35 - mixture of 32% -1,4 dimethylpiperazine 32% and 40% nonylphenol, ethoxylated
0,30 - полимерна пигментна смес0.30 - polymer pigment mixture
10,0 - смес от олигомерни хлоретилфосфати10.0 - a mixture of oligomeric chloroethyl phosphates
Получената по примера естерна, мека, блокова ПУ пяна е с плътност 30 kg/m3 по DIN 53420 и твърдост 4,0 kPa по DIN 53577, трудногорима по БДС 10457-88, подходяща за каширане с текстили по пламъчен метод:The ester, soft, block PU foam, obtained by the example, has a density of 30 kg / m 3 according to DIN 53420 and a hardness of 4.0 kPa according to DIN 53577, non-flammable according to BDS 10457-88, suitable for laminating with textiles by flame method:
Технологията включва същата последователност от операции и технологичен режим както в Пример 1.The technology includes the same sequence of operations and process mode as in Example 1.
Пример 3. Съставът по примера съдържа:Example 3. The composition of the example contains:
100,00 - полиестерполиол с хидроксилно число 60100.00 - polyester polyol with hydroxyl number 60
43,20 - смес 2:1 от 2,4 и 2,6 толуилендиизоцианат в съотношение 80:20 и43.20 - a mixture of 2: 1 of 2,4 and 2,6 toluylenediisocyanate in a ratio of 80:20 and
2,4 и 2,6 толуилендиизоцианат в съотношение 65:352,4 and 2,6 toluylenediisocyanate at 65:35
3,5 - вода3,5 - water
1.10 - смес от модифицирани полиетерни полисилоксани и тензиди1.10 - mixture of modified polyether polysiloxanes and surfactants
0,45 - смес в съотношение 1:1,5 на бис(2-диметиламиноетил)етер и нейоногенно повърхностно активно вещество към 1,4 диметилпиперазин0.45 - 1: 1.5 mixture of bis (2-dimethylaminoethyl) ether and non-ionic surfactant to 1,4 dimethylpiperazine
0,20 - дисперсен ПУ пигмент0,20 - dispersed PU pigment
10,00 - микронизиран калциев карбонат със среден размер на частиците 2,48μ, повърхностно обработен със стеаринова киселина.10.00 - Micronized calcium carbonate with a mean particle size of 2.48µ, surface treated with stearic acid.
По примерния състав се получава напълнена естерна, мека, блокова ПУ пяна с плътност 35 kg/m3 по DIN 53420 и твърдост 5,2 kPa по DIN 53577:According to the example composition, a filled ester, soft, block PU foam with a density of 35 kg / m 3 according to DIN 53420 and a hardness of 5.2 kPa according to DIN 53577 is obtained:
Технологията включва ·* ····Technology includes · * ····
операциите,operations,
описани в пример!.,като допълнително предварително се подготвя смес от креда и полиол в съотношение 1:2. Сместа се подава към смесителната камера на разпенващата инсталация.described in Example 1, additionally preparing a mixture of chalk and polyol in a 1: 2 ratio. The mixture is fed to the mixing chamber of the blowing plant.
Пример 4. Съставът по примера съдържа:Example 4. The composition of the example contains:
100,00 - полиестерполиол с хидроксилно число 60100.00 - polyester polyol with hydroxyl number 60
50,20 - 2,4 и 2,6 толуилендиизоцианат в съотношение 80:2050.20 - 2.4 and 2.6 toluylenediisocyanate in the ratio 80:20
4,50 - вода4,50 - water
0,85 - смес от модифицирани полиетерни полисилоксани и тензиди0.85 - a mixture of modified polyether polysiloxanes and surfactants
1,00 -смес от 25% -1,4 диметилпиперазин и бис(2диметиламиноетил)етер 20%1.00 -mix of 25% -1.4 dimethylpiperazine and bis (2dimethylaminoethyl) ether 20%
0,60 - полимерна пигментна смес0.60 - polymer pigment mixture
1,00 - алкилсулфонкиселинен естер на фенола (мезамол)1,00 - Phenol alkyl sulfonic acid ester (mesamol)
0,03 - триглицерид на стеариновата киселина (стеарин)0,03 - Stearic acid triglyceride (stearin)
0,45 - смес от децил дифенил фосфат и бензоатен дериват и фенолен дериват от 25 до 50.0,45 - mixture of decyl diphenyl phosphate and benzoate derivative and phenolic derivative from 25 to 50.
Технологията включва операциите, описани в Пример 1, като допълнително предварително се подготвя смес от триглицерид на 'Ч стеариновата киселина и мезамол в количества, съобразно рецептурата. Сместа се подава към полиола непосредствено преди смесителната камера на разпенващата инсталация.Съставът по примера е на естерна, мека, блокова ПУ пяна с плътност 25 kg/m3 по DIN 53420 и неравномерноедропореста структура за гъби.The technology involves the operations described in Example 1 by additionally preparing a mixture of triglyceride of 1 H stearic acid and mesamol in amounts according to the formulation. The mixture is fed to the polyol immediately before the mixing chamber of the blowing plant. The example composition is an ester, soft, block PU foam with a density of 25 kg / m 3 according to DIN 53420 and an uneven porous mushroom structure.
Пример 5. Съставът по примера съдържа :Example 5. The composition of the example contains:
100,00 - полиестерполиол с хидроксилно число 60100.00 - polyester polyol with hydroxyl number 60
44,10 - 2,4 и 2,6 толуилендиизоцианат в съотношение 65:3544.10 - 2.4 and 2.6 toluylenediisocyanate 65:35
3,5 - вода3,5 - water
0,85 - смес от модифицирани полиетерни полисилоксани и тензиди0.85 - a mixture of modified polyether polysiloxanes and surfactants
• · · · · • ·· • · · • ·· · ·· ·• · · · · · · · · · · · · · · · ·
0,45 - диамвд на въглеродната киселина(карбамид)0.45 - carbon dioxide (urea)
0,40 - 1,4 диметилпиперазин0.40 - 1.4 dimethylpiperazine
0,80 - полимерна пигментна смес0.80 - polymer pigment mixture
3,20 - алкилсулфонкиселинен естер на фенола (мезамол)3,20 - Phenol alkyl sulfonic acid ester (mesamol)
0,02 - силиконово масло0.02 - silicone oil
Технологията включва операциите, описани в пример 1. но предварително се подготвя смес от силиконово масло и алкилсулфонкиселинен естер на фенола в количества, съобразно рецептурата. Сместа се подава към полиола непосредствено преди смесителната камера на разпенващата инсталация. Предварително се подготвя и разтвор на диамид на въглеродната киселина във вода в количества, съобразно рецептурата и се подава директнао в смесителната камера на разпенващата инсталация.The technology involves the operations described in Example 1. but a mixture of silicone oil and the alkylsulfonic acid ester of phenol is prepared in advance according to the recipe. The mixture is fed to the polyol immediately before the mixing chamber of the blowing plant. A solution of carbonic acid diamide in water in quantities according to the recipe is prepared in advance and fed directly into the mixing chamber of the blowing plant.
Съставът по примера е за получаване на естерна, мека, блокова ПУ пяна с плътност 35 kg/m3 по DIN 53420 и груба, равномерно-едропореста структура.The composition of the example is for the preparation of an ester, soft, block PU foam with a density of 35 kg / m 3 according to DIN 53420 and a coarse, evenly-porous structure.
Claims (9)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18271000P | 2000-02-15 | 2000-02-15 | |
US21642200P | 2000-07-06 | 2000-07-06 | |
US24353200P | 2000-10-27 | 2000-10-27 |
Publications (2)
Publication Number | Publication Date |
---|---|
BG107078A true BG107078A (en) | 2003-04-30 |
BG65764B1 BG65764B1 (en) | 2009-10-30 |
Family
ID=27391578
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BG107078A BG65764B1 (en) | 2000-02-15 | 2002-09-10 | Pyrrole-substituted 2-indolinone protein kinase inhibitors |
Country Status (43)
Families Citing this family (331)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6569868B2 (en) | 1998-04-16 | 2003-05-27 | Sugen, Inc. | 2-indolinone derivatives as modulators of protein kinase activity |
US20040226056A1 (en) * | 1998-12-22 | 2004-11-11 | Myriad Genetics, Incorporated | Compositions and methods for treating neurological disorders and diseases |
BR0007532A (en) | 1999-01-13 | 2001-11-20 | Univ New York State Res Found | Methods to identify protein kinase inhibitors, to test compounds for a capacity to inhibit protein kinase activity and to inhibit a protein kinase, non-peptide protein tyrosine kinase inhibitor, and, method of treating a condition responsive to a protein kinase inhibitor in a patient |
CA2399358C (en) * | 2000-02-15 | 2006-03-21 | Sugen, Inc. | Pyrrole substituted 2-indolinone protein kinase inhibitors |
US7030219B2 (en) | 2000-04-28 | 2006-04-18 | Johns Hopkins University | B7-DC, Dendritic cell co-stimulatory molecules |
MY128450A (en) | 2000-05-24 | 2007-02-28 | Upjohn Co | 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives |
EP1294688A2 (en) | 2000-06-02 | 2003-03-26 | Sugen, Inc. | Indolinone derivatives as protein kinase/phosphatase inhibitors |
WO2002002551A1 (en) * | 2000-06-30 | 2002-01-10 | Sugen, Inc. | 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors |
ES2318649T3 (en) | 2000-10-20 | 2009-05-01 | EISAI R&D MANAGEMENT CO., LTD. | PROCEDURE FOR PREPARATION OF DERIVATIVES OF 4-FENOXI QUINOLINAS. |
JP2004518669A (en) | 2000-12-20 | 2004-06-24 | スージェン・インコーポレーテッド | 4-Aryl substituted indolinone |
AR042586A1 (en) * | 2001-02-15 | 2005-06-29 | Sugen Inc | 3- (4-AMIDOPIRROL-2-ILMETILIDEN) -2-INDOLINONE AS INHIBITORS OF PROTEIN KINASE; YOUR PHARMACEUTICAL COMPOSITIONS; A METHOD FOR THE MODULATION OF THE CATALYTIC ACTIVITY OF PROTEINQUINASE; A METHOD TO TREAT OR PREVENT AN AFFECTION RELATED TO PROTEINQUINASE |
EP1247809A3 (en) * | 2001-03-30 | 2003-12-17 | Pfizer Products Inc. | Triazine compounds useful as sorbitol dehydrogenase inhibitors |
US6599902B2 (en) | 2001-05-30 | 2003-07-29 | Sugen, Inc. | 5-aralkysufonyl-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors |
DE60227709D1 (en) * | 2001-06-29 | 2008-08-28 | Ab Science | THE USE OF C-CRITERIA FOR THE TREATMENT OF AUTOIMMUNE DISEASES |
AR038957A1 (en) * | 2001-08-15 | 2005-02-02 | Pharmacia Corp | COMBINATION THERAPY FOR CANCER TREATMENT |
RS53251B (en) * | 2001-08-15 | 2014-08-29 | Pharmacia & Upjohn Company Llc | Crystals including a malic acid salt of n-[2-(diethylamino) ethyl]-5-[(5-fluoro-2-oxo-3h-indole-3-ylidene)methyl]-2,4- dimethyl-1h-pyrrole-3-carboxamide, processes for its preparation and compositions thereof |
WO2003022815A1 (en) * | 2001-09-10 | 2003-03-20 | Sugen, Inc. | 3-(4,5,6,7-tetrahydroindol-2-ylmethylidiene)-2-indolinone derivatives as kinase inhibitors |
JP2005508953A (en) * | 2001-10-10 | 2005-04-07 | スージェン・インコーポレーテッド | 3- [4- (Substituted heterocyclyl) -pyrrol-2-ylmethylidene] -2-indolinone derivatives as kinase inhibitors |
WO2003035621A1 (en) * | 2001-10-22 | 2003-05-01 | The Research Foundation Of State University Of New York | Protein kinase and phosphatase inhibitors, methods for designing them, and methods of using them |
US7005445B2 (en) | 2001-10-22 | 2006-02-28 | The Research Foundation Of State University Of New York | Protein kinase and phosphatase inhibitors and methods for designing them |
US20030080191A1 (en) * | 2001-10-26 | 2003-05-01 | Allen Lubow | Method and apparatus for applying bar code information to products during production |
TWI259081B (en) * | 2001-10-26 | 2006-08-01 | Sugen Inc | Treatment of acute myeloid leukemia with indolinone compounds |
US6797825B2 (en) | 2001-12-13 | 2004-09-28 | Abbott Laboratories | Protein kinase inhibitors |
US20030187026A1 (en) | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
WO2003052681A1 (en) * | 2001-12-17 | 2003-06-26 | International Barcode Corporation | Double-sided bar code doubling as a single bar code |
US20050131733A1 (en) * | 2001-12-17 | 2005-06-16 | Allen Lubow | Sealable individual bar coded packets |
AU2002360753B2 (en) | 2001-12-27 | 2008-08-21 | Theravance, Inc. | Indolinone derivatives useful as protein kinase inhibitors |
AU2003216282A1 (en) * | 2002-02-15 | 2003-09-09 | Pharmacia And Upjohn Company Llc | Process for preparing indolinone derivatives |
US20040018528A1 (en) * | 2002-05-17 | 2004-01-29 | Sugen, Inc. | Novel biomarkers of tyrosine kinase inhibitor exposure and activity in mammals |
ITMI20021620A1 (en) * | 2002-07-23 | 2004-01-23 | Novuspharma Spa | ANTI-TUMORAL ACTIVITY COMPOUND |
US20060084697A1 (en) * | 2002-08-08 | 2006-04-20 | Hallahan Dennis E | Pi3k antagonists as radiosensitizers |
EP1576129A4 (en) * | 2002-08-09 | 2008-01-23 | Theravance Inc | Oncokinase fusion polypeptides associated with hyperproliferative and related disorders, nucleic acids encoding the same and methods for detecting and identifying the same |
US20040121407A1 (en) * | 2002-09-06 | 2004-06-24 | Elixir Pharmaceuticals, Inc. | Regulation of the growth hormone/IGF-1 axis |
HN2003000272A (en) * | 2002-09-10 | 2008-07-29 | Pharmacia Italia Spa | FORMULATIONS THAT INCLUDE AN INDOLINONE COMPOUND |
AR042042A1 (en) * | 2002-11-15 | 2005-06-08 | Sugen Inc | COMBINED ADMINISTRATION OF AN INDOLINONE WITH A CHEMOTHERAPEUTIC AGENT FOR CELL PROLIFERATION DISORDERS |
US7626031B2 (en) * | 2002-11-15 | 2009-12-01 | Symphony Evolution, Inc. | Substituted 3-(diarylmethylene)indolin-2-ones and methods of their use |
US20040209937A1 (en) * | 2003-02-24 | 2004-10-21 | Sugen, Inc. | Treatment of excessive osteolysis with indolinone compounds |
US7452913B2 (en) * | 2003-02-24 | 2008-11-18 | Pharmacia & Upjohn Company | Polymorphs of pyrrole substituted 2-indolinone protein kinase inhibitors |
GEP20084341B (en) | 2003-02-26 | 2008-03-25 | Sugen Inc | Aminoheteroaryl compounds as protein kinase inhibitors |
US7157577B2 (en) * | 2003-03-07 | 2007-01-02 | Sugen Inc. | 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors |
US20040266843A1 (en) * | 2003-03-07 | 2004-12-30 | Sugen, Inc. | Sulfonamide substituted indolinones as inhibitors of DNA dependent protein kinase (DNA-PK) |
US7994159B2 (en) * | 2003-03-10 | 2011-08-09 | Eisai R&D Management Co., Ltd. | c-Kit kinase inhibitor |
US20050043233A1 (en) | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
DE10334582A1 (en) * | 2003-07-28 | 2005-02-24 | Basf Ag | Maleic anhydride production by VPO-catalyzed gas-phase oxidation of n- butane involves setting the n-butane and oxygen content levels in a pressure- controlled feed to reduce risk of explosions |
WO2005023765A1 (en) * | 2003-09-11 | 2005-03-17 | Pharmacia & Upjohn Company Llc | Method for catalyzing amidation reactions by the presence of co2 |
KR20060058728A (en) * | 2003-10-02 | 2006-05-30 | 파마시아 앤드 업존 캄파니 엘엘씨 | Salts and polymorphs of a pyrrole-substituted indolinone compound |
CA2542638A1 (en) * | 2003-10-16 | 2005-04-28 | Imclone Systems Incorporated | Fibroblast growth factor receptor-1 inhibitors and methods of treatment thereof |
TWI347940B (en) | 2003-11-07 | 2011-09-01 | Novartis Ag | Methods for synthesizing quinolinone compounds |
CN101337930B (en) | 2003-11-11 | 2010-09-08 | 卫材R&D管理有限公司 | Urea derivative preparation process |
JP2007512353A (en) * | 2003-11-26 | 2007-05-17 | ザ スクリプス リサーチ インスティテュート | Highly functional indolinone protein kinase inhibitor |
EP1699477A2 (en) * | 2003-12-11 | 2006-09-13 | Theravance, Inc. | Compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases |
US20050152943A1 (en) * | 2003-12-23 | 2005-07-14 | Medtronic Vascular, Inc. | Medical devices to treat or inhibit restenosis |
WO2005118543A1 (en) * | 2004-06-03 | 2005-12-15 | Ono Pharmaceutical Co., Ltd. | Kinase inhibitor and use thereof |
CA2571421A1 (en) | 2004-06-24 | 2006-01-05 | Nicholas Valiante | Compounds for immunopotentiation |
SE0401790D0 (en) * | 2004-07-07 | 2004-07-07 | Forskarpatent I Syd Ab | Tamoxifen response in pre- and postmenopausal breast cancer patients |
US20060009510A1 (en) * | 2004-07-09 | 2006-01-12 | Pharmacia & Upjohn Company Llc | Method of synthesizing indolinone compounds |
ATE463486T1 (en) * | 2004-08-26 | 2010-04-15 | Pfizer | ENANTIOMER PURE AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS |
US8969379B2 (en) | 2004-09-17 | 2015-03-03 | Eisai R&D Management Co., Ltd. | Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7=methoxy-6-quinolinecarboxide |
CN100432071C (en) * | 2004-11-05 | 2008-11-12 | 中国科学院上海药物研究所 | Substituted 1H-indole-2-ketone compound and its preparation method and uses |
GT200500321A (en) * | 2004-11-09 | 2006-09-04 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF PROTEIN KINASE. | |
BRPI0607579A2 (en) * | 2005-03-23 | 2009-09-15 | Pfizer Prod Inc | use of anti-ctla4 antibody and indolinone for the preparation of cancer treatment drugs |
BRPI0608096A2 (en) | 2005-04-26 | 2009-11-10 | Pfizer | p-cadherin antibodies |
WO2006120557A1 (en) * | 2005-05-12 | 2006-11-16 | Pfizer Inc. | Anticancer combination therapy using sunitinib malate |
TWI441637B (en) | 2005-05-18 | 2014-06-21 | Array Biopharma Inc | Heterocyclic inhibitors of mek and methods of use thereof |
EP2266974A1 (en) | 2005-05-23 | 2010-12-29 | Novartis AG | Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-Quinolin-2-one lactic acid salts |
MX2007014810A (en) * | 2005-05-26 | 2008-02-21 | Scripps Research Inst | Enhanced indolinone based protein kinase inhibitors. |
US20100105031A1 (en) * | 2005-08-01 | 2010-04-29 | Esai R & D Management Co., Ltd. | Method for prediction of the efficacy of vascularization inhibitor |
WO2007015578A1 (en) | 2005-08-02 | 2007-02-08 | Eisai R & D Management Co., Ltd. | Method for assay on the effect of vascularization inhibitor |
UA94060C2 (en) | 2005-09-07 | 2011-04-11 | Эмджен Фримонт Инк. | Monoclonal antibodies that specifically binds alk-1 |
PL1928858T3 (en) * | 2005-09-19 | 2009-12-31 | Zoetis Services Llc | Solid salt forms of a pyrrole substituted 2-indolinone |
WO2007052849A1 (en) * | 2005-11-07 | 2007-05-10 | Eisai R & D Management Co., Ltd. | USE OF COMBINATION OF ANTI-ANGIOGENIC SUBSTANCE AND c-kit KINASE INHIBITOR |
UA96139C2 (en) | 2005-11-08 | 2011-10-10 | Дженентек, Інк. | Anti-neuropilin-1 (nrp1) antibody |
BRPI0620939A2 (en) * | 2005-12-29 | 2011-11-29 | Scripps Research Inst | indolinone amino acid derivatives based on protein kinase inhibitors |
JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | PI-3 Kinase inhibitors and methods of their use |
CN101007801A (en) * | 2006-01-27 | 2007-08-01 | 上海恒瑞医药有限公司 | Pyrrole substituted 2-dihydromolindone derivative, its preparation method and medical uses |
TW200808739A (en) | 2006-04-06 | 2008-02-16 | Novartis Vaccines & Diagnostic | Quinazolines for PDK1 inhibition |
TW200813091A (en) | 2006-04-10 | 2008-03-16 | Amgen Fremont Inc | Targeted binding agents directed to uPAR and uses thereof |
CN101472915A (en) | 2006-04-19 | 2009-07-01 | 诺瓦提斯公司 | Indazole compounds and methods for inhibition of CDC7 |
EA200802058A1 (en) | 2006-05-09 | 2009-06-30 | Пфайзер Продактс Инк. | DERIVATIVES OF CYCLO-ALKYLAMINO ACIDS AND THEIR PHARMACEUTICAL COMPOSITIONS |
CA2652442C (en) | 2006-05-18 | 2014-12-09 | Eisai R & D Management Co., Ltd. | Antitumor agent for thyroid cancer |
DE102006024834B4 (en) * | 2006-05-24 | 2010-07-01 | Schebo Biotech Ag | New indole pyrrole derivatives and their uses |
US7838542B2 (en) | 2006-06-29 | 2010-11-23 | Kinex Pharmaceuticals, Llc | Bicyclic compositions and methods for modulating a kinase cascade |
JPWO2008001956A1 (en) * | 2006-06-29 | 2009-12-03 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Liver fibrosis treatment |
WO2008008981A1 (en) | 2006-07-13 | 2008-01-17 | Zymogenetics, Inc. | Interleukin 21 and tyrosine kinase inhibitor combination therapy |
CL2007002225A1 (en) | 2006-08-03 | 2008-04-18 | Astrazeneca Ab | SPECIFIC UNION AGENT FOR A RECEIVER OF THE GROWTH FACTOR DERIVED FROM PLATES (PDGFR-ALFA); NUCLEIC ACID MOLECULA THAT CODIFIES IT; VECTOR AND CELL GUESTS THAT UNDERSTAND IT; CONJUGADO UNDERSTANDING THE AGENT; AND USE OF THE AGENT OF A |
JP5238697B2 (en) | 2006-08-04 | 2013-07-17 | 武田薬品工業株式会社 | Fused heterocyclic derivatives and uses thereof |
JP5227321B2 (en) | 2006-08-23 | 2013-07-03 | クドス ファーマシューティカルズ リミテッド | 2-Methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as MTOR inhibitors |
KR101472600B1 (en) * | 2006-08-28 | 2014-12-15 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | Antitumor agent for undifferentiated gastric cancer |
AU2007294686B2 (en) | 2006-09-15 | 2013-10-31 | Equinox Sciences, Llc | Kinase inhibitor compounds |
WO2008056634A1 (en) * | 2006-11-06 | 2008-05-15 | Theravalues Corporation | Novel hydroxyindole derivative |
NZ576234A (en) | 2006-11-06 | 2011-06-30 | Supergen Inc | Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors |
JP5542445B2 (en) | 2006-12-04 | 2014-07-09 | 江▲蘇▼先声▲薬▼物研究有限公司 | 3-pyrrolocyclohexylidene-2-dihydroindolinone derivatives and uses thereof |
CA2676796C (en) | 2007-01-29 | 2016-02-23 | Eisai R & D Management Co., Ltd. | Composition for treatment of undifferentiated gastric cancer |
MX2009008386A (en) | 2007-02-06 | 2009-10-16 | Pfizer | 2-amin0-5, 7-dihydr0-6h- pyrrolo [3, 4-d] pyrimidine derivatives as hsp-90 inhibitors for treating cancer. |
JPWO2008114819A1 (en) | 2007-03-20 | 2010-07-08 | 大日本住友製薬株式会社 | New adenine compounds |
US20090004213A1 (en) * | 2007-03-26 | 2009-01-01 | Immatics Biotechnologies Gmbh | Combination therapy using active immunotherapy |
US20090042906A1 (en) * | 2007-04-26 | 2009-02-12 | Massachusetts Institute Of Technology | Methods for treating cancers associated with constitutive egfr signaling |
WO2008138184A1 (en) | 2007-05-14 | 2008-11-20 | Shanghai Hengrui Pharmaceutical Co.Ltd. | Derivatives of pyrroloazacycles, the method of making them and the use thereof as inhibitors of protein kinases |
WO2008145398A1 (en) * | 2007-06-01 | 2008-12-04 | Pfizer Italia S.R.L. | 4-arylpyrrole substituted 2-indoline derivatives active as protein kinase inhibitors |
PE20090370A1 (en) | 2007-06-05 | 2009-04-30 | Takeda Pharmaceutical | DERIVATIVES OF FUSED HETEROCYCLE AS KINASE INHIBITORS |
WO2009025358A1 (en) | 2007-08-23 | 2009-02-26 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
US20090062368A1 (en) * | 2007-08-29 | 2009-03-05 | Protia, Llc | Deuterium-enriched sunitinib |
PT2197878T (en) * | 2007-09-06 | 2016-11-04 | Boston Biomedical Inc | Compositions of kinase inhibitors and their use for treatment of cancer and other diseases related to kinases |
CN101861321B (en) | 2007-10-11 | 2013-02-06 | 阿斯利康(瑞典)有限公司 | Pyrrolo [2, 3 -D] pyrimidin derivatives as protein kinase B inhibitors |
WO2009060945A1 (en) | 2007-11-09 | 2009-05-14 | Eisai R & D Management Co., Ltd. | Combination of anti-angiogenic substance and anti-tumor platinum complex |
WO2009067686A2 (en) * | 2007-11-21 | 2009-05-28 | Teva Pharmaceutical Industries Ltd. | Sunitinib hemi-l-malate, polymorphs and preparation thereof, polymorphs of racemic sunitinib malate, compositins containing sunitinib base and malic acid and preparation thereof |
US20100256392A1 (en) * | 2007-11-21 | 2010-10-07 | Teva Pharmaceutical Industries Ltd. | Polymorphs of sunitinib base and processes for preparation thereof |
CA2709083A1 (en) * | 2007-12-12 | 2009-06-18 | Medichem S.A. | Polymorphic forms of a 3-pyrrole substituted 2-indolinone |
CA2706571C (en) | 2007-12-19 | 2012-11-27 | Genentech, Inc. | 5-anilinoimidazopyridines and methods of use |
CN101952282A (en) | 2007-12-20 | 2011-01-19 | 诺瓦提斯公司 | Thiazole derivatives used as PI 3 kinase inhibitors |
KR20100099185A (en) | 2007-12-21 | 2010-09-10 | 제넨테크, 인크. | Azaindolizines and methods of use |
AU2009210098B2 (en) * | 2008-01-29 | 2013-06-13 | Eisai R & D Management Co., Ltd. | Combined use of angiogenesis inhibitor and taxane |
EP2240174A1 (en) * | 2008-02-13 | 2010-10-20 | Ratiopharm GmbH | Pharmaceutical compositions comprising n-ý2-(diethylamino)ethyl¨-5-ý(5-fluoro-1,2- dihydro-2-oxo-3h-indol-3-ylidene)methyl¨-2,4-dimethyl-1h-pyrrole-3-carboxamide |
EP2113248A1 (en) | 2008-04-29 | 2009-11-04 | Ratiopharm GmbH | Pharmaceutical composition comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-,4-dimethyl-1H-pyrrole-3-carboxamide |
EP2090306A1 (en) | 2008-02-13 | 2009-08-19 | Ratiopharm GmbH | Pharmaceutical compositions comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide |
CN101255154B (en) * | 2008-02-18 | 2011-09-07 | 靳广毅 | Substituted 2-indoline ketone derivatives as well as preparation method and uses thereof |
CA2715657A1 (en) * | 2008-02-21 | 2009-08-27 | Generics (Uk) Limited | Novel polymorphs and processes for their preparation |
EP2098521A1 (en) * | 2008-03-06 | 2009-09-09 | Ratiopharm GmbH | Crystal forms of N-[2-(diethylamino) ethyl]-5-[fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrolle-3-carboxamide and methods for their prepparation |
EP2274303B1 (en) * | 2008-03-31 | 2012-08-29 | Teva Pharmaceutical Industries Ltd. | Processes for preparing sunitinib and salts thereof |
EP2280960A1 (en) | 2008-04-16 | 2011-02-09 | Natco Pharma Limited | Novel polymorphic forms of sunitinib base |
US8158656B2 (en) * | 2008-05-16 | 2012-04-17 | Shenzhen Chipscreen Biosciences Ltd. | 2-indolinone derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors |
EP2292613B1 (en) * | 2008-05-23 | 2015-09-30 | Shanghai Institute of Pharmaceutical Industry | Dihydroindolinone derivatives |
WO2009154697A2 (en) | 2008-05-28 | 2009-12-23 | Massachusetts Institute Of Technology | Disc-1 pathway activators in the control of neurogenesis |
SI2313371T1 (en) * | 2008-06-13 | 2013-02-28 | Medichem, S.A. | Process for preparing a 3-pyrrole substituted 2-indolinone malate salt |
WO2009157011A1 (en) * | 2008-06-23 | 2009-12-30 | Natco Pharma Limited | Process for the preparation of high purity sunitinib and its pharmaceutically acceptable salt |
EP2138167A1 (en) * | 2008-06-24 | 2009-12-30 | ratiopharm GmbH | Pharmaceutical composition comprising N-[2-(Diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene) methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide |
WO2009156837A2 (en) * | 2008-06-26 | 2009-12-30 | Medichem, S.A. | Amorphous form of a 3-pyrrole substituted 2-indolinone malate salt |
CN102137866A (en) * | 2008-06-30 | 2011-07-27 | 赛林药物股份有限公司 | Oxindole compounds |
DE102008031038A1 (en) | 2008-06-30 | 2009-12-31 | Alexander Priv.-Doz. Dr. Dömling | Use of 2-indolinone derivatives for the treatment of organ transplantation |
SG10201510586PA (en) | 2008-06-30 | 2016-01-28 | Mesoblast Inc | Treatment of Eye Diseases And Excessive Neovascularization Using A Combined Therapy |
JP2011526615A (en) * | 2008-07-02 | 2011-10-13 | ジェネリクス・(ユーケー)・リミテッド | Preparation of 3-pyrrole substituted 2-indolinone derivatives |
JP2011527330A (en) * | 2008-07-10 | 2011-10-27 | ジェネリクス・(ユーケー)・リミテッド | Preparation method of crystalline form of sunitinib malate |
KR20110036588A (en) | 2008-07-24 | 2011-04-07 | 테바 파마슈티컬 인더스트리즈 리미티드 | Sunitinib and salts thereof and their polymorphs |
CN102164913A (en) | 2008-07-24 | 2011-08-24 | 麦迪凯姆股份公司 | Crystalline forms of a 3-pyrrole substituted 2-indolinone malate salt |
US8993615B2 (en) * | 2008-08-08 | 2015-03-31 | The Johns Hopkins University | Compositions and methods for treatment of neurodegenerative disease |
US20110263670A1 (en) * | 2008-08-25 | 2011-10-27 | Vinayak Gore | Novel polymorphs of sunitinib and processes for their preparation |
US20110159023A1 (en) * | 2008-08-25 | 2011-06-30 | Solomon Langermann | Pd-1 antagonists and methods for treating infectious disease |
JP2012500837A (en) * | 2008-08-25 | 2012-01-12 | ジェネリクス・(ユーケー)・リミテッド | Novel crystal form and preparation method thereof |
NZ591130A (en) | 2008-08-25 | 2012-09-28 | Amplimmune Inc | Compositions comprising a PD-1 antagonists and cyclophosphamide and methods of use thereof |
US8961930B2 (en) * | 2008-09-05 | 2015-02-24 | Imperial Innovations Limited | Isatin derivatives for use as in vivo imaging agents |
EP2927244A1 (en) | 2008-09-19 | 2015-10-07 | MedImmune, LLC | Antibodies directed to DLL4 and uses thereof |
AR073807A1 (en) * | 2008-10-10 | 2010-12-01 | Medichem Sa | PROCESS TO PREPARE SUNITINIB MALATE, SALT OF A WEAKER ACID THAN MALATE AS A INTERMEDIARY COMPOUND, AND PROCESS TO PREPARE SUCH INTERMEDIARY SALT. |
EP2181991A1 (en) | 2008-10-28 | 2010-05-05 | LEK Pharmaceuticals D.D. | Novel salts of sunitinib |
EP2186809A1 (en) * | 2008-11-13 | 2010-05-19 | LEK Pharmaceuticals D.D. | New crystal form of sunitinib malate |
US20100222371A1 (en) * | 2008-11-20 | 2010-09-02 | Children's Medical Center Corporation | Prevention of surgical adhesions |
WO2010064611A1 (en) | 2008-12-01 | 2010-06-10 | 武田薬品工業株式会社 | Heterocyclic compound and use thereof |
JO3101B1 (en) | 2008-12-02 | 2017-09-20 | Takeda Pharmaceuticals Co | Benzothiazole derivatives as anticancer agents |
US20110053923A1 (en) | 2008-12-22 | 2011-03-03 | Astrazeneca | Chemical compounds 610 |
EP2379595A2 (en) | 2008-12-23 | 2011-10-26 | AstraZeneca AB | Targeted binding agents directed to 5 1 and uses thereof |
EP2373643A4 (en) | 2009-01-02 | 2013-08-07 | Hetero Research Foundation | Novel polymorphs of sunitinib malate |
KR20200137052A (en) | 2009-01-16 | 2020-12-08 | 엑셀리시스, 인코포레이티드 | Malate salt of n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer |
EP3360879A1 (en) | 2009-02-05 | 2018-08-15 | ImmunoGen, Inc. | Benzodiazepine derivatives as cytotoxic agents |
SG172857A1 (en) | 2009-02-09 | 2011-08-29 | Supergen Inc | Pyrrolopyrimidinyl axl kinase inhibitors |
US9265764B2 (en) * | 2009-02-27 | 2016-02-23 | Massachusetts Institute Of Technology | Uses of chemicals to modulate GSK-3 signaling for treatment of bipolar disorder and other brain disorders |
US20100222381A1 (en) | 2009-02-27 | 2010-09-02 | Hariprasad Vankayalapati | Cyclopentathiophene/cyclohexathiophene DNA methyltransferase inhibitors |
WO2010103094A1 (en) | 2009-03-13 | 2010-09-16 | Cellzome Limited | PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS |
WO2010108503A1 (en) | 2009-03-24 | 2010-09-30 | Life & Brain Gmbh | Promotion of neuronal integration in neural stem cell grafts |
EP2419423A1 (en) | 2009-04-14 | 2012-02-22 | Cellzome Limited | Fluoro substituted pyrimidine compounds as jak3 inhibitors |
US8530492B2 (en) | 2009-04-17 | 2013-09-10 | Nektar Therapeutics | Oligomer-protein tyrosine kinase inhibitor conjugates |
EP2255792A1 (en) | 2009-05-20 | 2010-12-01 | Ratiopharm GmbH | Pharmaceutical compositions for N-[2-(Diethylamino)ethyl]5-[(fluoro-1,2-dihydro-2-oxo-3H-indole-3-ylidene) methyl]-2,4-dimenthyl-1H-pyrrole-3-carboxamide |
US8211901B2 (en) | 2009-05-22 | 2012-07-03 | Shenzhen Chipscreen Biosciences Ltd. | Naphthamide derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors |
EP2264027A1 (en) * | 2009-05-27 | 2010-12-22 | Ratiopharm GmbH | Process for the preparation of N-[2-(Diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene) methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide |
US8389580B2 (en) | 2009-06-02 | 2013-03-05 | Duke University | Arylcyclopropylamines and methods of use |
CN101906076B (en) | 2009-06-04 | 2013-03-13 | 深圳微芯生物科技有限责任公司 | Naphthaline amide derivative serving as protein kinase inhibitor and histone deacetylase inhibitor and preparation method and application thereof |
US8293753B2 (en) | 2009-07-02 | 2012-10-23 | Novartis Ag | Substituted 2-carboxamide cycloamino ureas |
WO2011004200A1 (en) | 2009-07-10 | 2011-01-13 | Generics [Uk] Limited | Novel pyrrole derivatives |
FR2948940B1 (en) * | 2009-08-04 | 2011-07-22 | Servier Lab | NOVEL DIHYDROINDOLONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
CA2771675A1 (en) | 2009-09-11 | 2011-03-17 | Cellzome Limited | Ortho substituted pyrimidine compounds as jak inhibitors |
WO2011033472A1 (en) | 2009-09-16 | 2011-03-24 | Ranbaxy Laboratories Limited | Salts of sunitinib |
MX2012004020A (en) | 2009-10-20 | 2012-05-08 | Cellzome Ltd | Heterocyclyl pyrazolopyrimidine analogues as jak inhibitors. |
EP2499133A2 (en) | 2009-11-12 | 2012-09-19 | Ranbaxy Laboratories Limited | Process for the preparation of crystalline form i of l-malic acid salt of sunitinib |
WO2011061613A1 (en) | 2009-11-19 | 2011-05-26 | Ranbaxy Laboratories Limited | Process for the preparation of crystalline form ii of l-malic acid salt of sunitinib |
NZ599405A (en) | 2009-11-24 | 2014-09-26 | Medimmune Ltd | Targeted binding agents against b7-h1 |
JP2013512859A (en) | 2009-12-03 | 2013-04-18 | 大日本住友製薬株式会社 | Imidazoquinoline acting through a toll-like receptor (TLR) |
US10166142B2 (en) | 2010-01-29 | 2019-01-01 | Forsight Vision4, Inc. | Small molecule delivery with implantable therapeutic device |
WO2011095802A1 (en) | 2010-02-02 | 2011-08-11 | Generics [Uk] Limited | Hplc method for analyzing sunitinib |
WO2011100325A2 (en) * | 2010-02-09 | 2011-08-18 | Sicor Inc. | Polymorphs of sunitinib salts |
CN102933231B (en) | 2010-02-10 | 2015-07-29 | 伊缪诺金公司 | CD20 antibody and uses thereof |
US8440651B2 (en) | 2010-02-22 | 2013-05-14 | F. Hoffmann-La Roche Ag | Pyrido[3,2-d]pyrimidine PI3K delta inhibitor compounds and methods of use |
WO2011104555A2 (en) * | 2010-02-25 | 2011-09-01 | Generics [Uk] Limited | Novel process |
CA2792039A1 (en) | 2010-03-04 | 2011-09-09 | Ranbaxy Laboratories Limited | Process for the direct preparation of malic acid salt of sunitinib |
EP2542536B1 (en) | 2010-03-04 | 2015-01-21 | Cellzome Limited | Morpholino substituted urea derivatives as mtor inhibitors |
WO2011110199A1 (en) | 2010-03-10 | 2011-09-15 | Synthon B.V. | A process for amidation of pyrrole carboxylate compounds |
US20160185760A1 (en) | 2010-03-18 | 2016-06-30 | Ranbaxy Laboratories Limited | Process for the preparation of malic acid salt of sunitinib |
EP2550263A4 (en) | 2010-03-23 | 2013-07-24 | Univ Johns Hopkins | Compositions and methods for treatment of neurodegenerative disease |
WO2011128699A2 (en) * | 2010-04-16 | 2011-10-20 | Generics [Uk] Limited | Novel process |
SG184989A1 (en) | 2010-04-30 | 2012-11-29 | Cellzome Ltd | Pyrazole compounds as jak inhibitors |
WO2011138565A1 (en) | 2010-05-05 | 2011-11-10 | Biorebus | Pharmaceutical combination containing lipoic acid, hydroxycitric acid and a somatostatin as active ingredients |
EP2392324A1 (en) | 2010-06-01 | 2011-12-07 | Societe De Coordination De Recherches Therapeutiques | Rhenium complexes and their pharmaceutical use |
SA111320519B1 (en) | 2010-06-11 | 2014-07-02 | Astrazeneca Ab | Pyrimidinyl Compounds for Use as ATR Inhibitors |
EP2586443B1 (en) | 2010-06-25 | 2016-03-16 | Eisai R&D Management Co., Ltd. | Antitumor agent using compounds having kinase inhibitory effect in combination |
US20130143915A1 (en) | 2010-07-01 | 2013-06-06 | Cellzome Limited | Triazolopyridines as tyk2 inhibitors |
NZ605449A (en) | 2010-07-09 | 2015-03-27 | Genentech Inc | Anti-neuropilin antibodies and methods of use |
AR082418A1 (en) | 2010-08-02 | 2012-12-05 | Novartis Ag | CRYSTAL FORMS OF 1- (4-METHYL-5- [2- (2,2,2-TRIFLUORO-1,1-DIMETHYL-Ethyl) -PIRIDIN-4-IL] -TIAZOL-2-IL) -AMIDE OF 2 -AMIDA OF THE ACID (S) -PIRROLIDIN-1,2-DICARBOXILICO |
WO2012022681A2 (en) | 2010-08-20 | 2012-02-23 | Cellzome Limited | Heterocyclyl pyrazolopyrimidine analogues as selective jak inhibitors |
WO2012027716A1 (en) | 2010-08-27 | 2012-03-01 | Collabrx, Inc. | Method to treat melanoma in braf inhibitor-resistant subjects |
WO2012042421A1 (en) | 2010-09-29 | 2012-04-05 | Pfizer Inc. | Method of treating abnormal cell growth |
WO2012058780A1 (en) | 2010-11-01 | 2012-05-10 | Scinopharm (Kunshan) Biochemical Technology Co., Ltd. | Processes for the preparation of 3-(pyrrol-2-yl)methylene)-2-pyrrolones using 2-silyloxy-pyrroles |
WO2012059941A1 (en) * | 2010-11-04 | 2012-05-10 | Ind-Swift Laboratories Limited | Process for preparation of sunitinib malate and salts thereof |
AU2011328237A1 (en) | 2010-11-09 | 2013-05-23 | Cellzome Limited | Pyridine compounds and aza analogues thereof as TYK2 inhibitors |
EP2640384A1 (en) | 2010-11-18 | 2013-09-25 | Synta Pharmaceuticals Corp. | Preselection of subjects for therapeutic treatment with oxygen sensitive agents based on hypoxic status |
CA2818612C (en) | 2010-11-19 | 2020-12-29 | Forsight Vision4, Inc. | Therapeutic agent formulations for implanted devices |
AR083868A1 (en) | 2010-12-03 | 2013-03-27 | Lilly Co Eli | OXAZOL COMPOUNDS [5,4-B] PIRIDIN-5-ILO |
JP6009457B2 (en) | 2010-12-23 | 2016-10-19 | ネクター セラピューティクス | Polymer-desethylsunitinib conjugate |
EP2654799B1 (en) | 2010-12-23 | 2017-11-08 | Nektar Therapeutics | Polymer-sunitinib conjugates |
AP2013007043A0 (en) | 2011-01-31 | 2013-08-31 | Novartis Ag | Novel heterocyclic derivatives |
MX346635B (en) | 2011-02-15 | 2017-03-27 | Immunogen Inc | Cytotoxic benzodiazepine derivatives. |
EP2675794B1 (en) | 2011-02-17 | 2019-02-13 | Cancer Therapeutics Crc Pty Limited | Selective fak inhibitors |
CA2827171C (en) | 2011-02-17 | 2019-04-09 | Cancer Therapeutics Crc Pty Limited | Fak inhibitors |
GB201103578D0 (en) | 2011-03-02 | 2011-04-13 | Sabrepharm Ltd | Dipyridinium derivatives |
US8630703B2 (en) | 2011-03-09 | 2014-01-14 | Technion Research & Development Foundation Limited | Treatment utilizing hydrophobic weak bases chemotherapeutic agents and illumination |
CN102115469A (en) * | 2011-03-21 | 2011-07-06 | 浙江大学 | Preparation method for indoline-2-one derivative and application of same |
WO2012136622A1 (en) | 2011-04-04 | 2012-10-11 | Cellzome Limited | Dihydropyrrolo pyrimidine derivatives as mtor inhibitors |
WO2012139019A2 (en) * | 2011-04-08 | 2012-10-11 | Beta Pharma, Inc. | New indolinone protein kinase inhibitors |
CA2828946C (en) | 2011-04-18 | 2016-06-21 | Eisai R&D Management Co., Ltd. | Therapeutic agent for tumor |
WO2012143320A1 (en) | 2011-04-18 | 2012-10-26 | Cellzome Limited | (7h-pyrrolo[2,3-d]pyrimidin-2-yl)amine compounds as jak3 inhibitors |
CN102898402B (en) * | 2011-04-26 | 2016-01-20 | 北京大学 | The indole ketone compound that the minaline ester that a kind of Benzisoelenazolone is modified replaces and application thereof |
ES2705950T3 (en) | 2011-06-03 | 2019-03-27 | Eisai R&D Man Co Ltd | Biomarkers to predict and assess the responsiveness of subjects with thyroid and kidney cancer to lenvatinib compounds |
ES2671748T3 (en) | 2011-07-21 | 2018-06-08 | Tolero Pharmaceuticals, Inc. | Heterocyclic protein kinase inhibitors |
KR20140047092A (en) | 2011-07-28 | 2014-04-21 | 셀좀 리미티드 | Heterocyclyl pyrimidine analogues as jak inhibitors |
WO2013017479A1 (en) | 2011-07-29 | 2013-02-07 | Cellzome Limited | Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors |
WO2013017480A1 (en) | 2011-07-29 | 2013-02-07 | Cellzome Limited | Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors |
WO2013041605A1 (en) | 2011-09-20 | 2013-03-28 | Cellzome Limited | Pyrazolo[4,3-c]pyridine derivatives as kinase inhibitors |
WO2013041652A1 (en) | 2011-09-21 | 2013-03-28 | Cellzome Limited | Morpholino substituted urea or carbamate derivatives as mtor inhibitors |
EP2763985B1 (en) | 2011-10-07 | 2016-06-22 | Cellzome Limited | {(4-(4-morpholino-dihydrothieno[3,4-d]pyrimidin-2-yl)aryl}urea or carbamate derivatives as mtor inhibitors |
CN102499917B (en) | 2011-10-25 | 2014-12-17 | 澳门大学 | Application of indolone compounds in preparing nerve protection medicine |
WO2013061305A1 (en) | 2011-10-28 | 2013-05-02 | Novartis Ag | Novel purine derivatives and their use in the treatment of disease |
CN103130774B (en) * | 2011-11-22 | 2016-06-22 | 齐鲁制药有限公司 | Compound with tyrosine kinase inhibitory activity and its preparation method and application |
CN103127096B (en) * | 2011-12-02 | 2015-11-25 | 杨子娇 | The Benzazole compounds that pyrrole radicals replaces is in the application for the treatment of glaucoma |
US20130178520A1 (en) | 2011-12-23 | 2013-07-11 | Duke University | Methods of treatment using arylcyclopropylamine compounds |
AU2012357038B2 (en) | 2011-12-23 | 2016-05-12 | Cellzome Limited | Pyrimidine-2,4-diamine derivatives as kinase inhibitors |
CN102491932A (en) * | 2011-12-26 | 2012-06-13 | 天津科技大学 | 3-indoline ketone derivative, and preparation method and application thereof |
US9206163B2 (en) | 2012-03-23 | 2015-12-08 | Laurus Labs Private Ltd. | Process for the preparation of sunitinib and its acid addition salts thereof |
EP2838538B1 (en) | 2012-04-20 | 2017-03-15 | Annji Pharmaceutical Co., Ltd. | Cyclopropanecarboxylate esters of purine analogues |
PL399027A1 (en) | 2012-04-27 | 2013-10-28 | Instytut Farmaceutyczny | Preparation method for high purity N- [2- (diethylamino) ethyl] -5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxamide and its use in the production of sunitinib |
CN102653521B (en) * | 2012-04-27 | 2014-08-06 | 首都师范大学 | Piperazine thiocarbohydrazide derivate of indole-2-ketone and preparation method and application of piperazine thiocarbohydrazide derivate |
DK2844282T3 (en) | 2012-05-04 | 2019-07-15 | Pfizer | PROSTATA ASSOCIATED ANTIGENES AND VACCINE-BASED IMMUNTERAPIREGIMENES |
JP6381523B2 (en) | 2012-05-16 | 2018-08-29 | ノバルティス アーゲー | Administration regimen of PI-3 kinase inhibitor |
AU2013270684B2 (en) | 2012-06-08 | 2018-04-19 | Sutro Biopharma, Inc. | Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use |
DK2863955T3 (en) | 2012-06-26 | 2017-01-23 | Sutro Biopharma Inc | MODIFIED FC PROTEINS, INCLUDING LOCATION-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, CONJUGATES THEREOF, METHODS OF PRODUCING ITS AND PROCEDURES FOR USE THEREOF |
US9238644B2 (en) | 2012-08-17 | 2016-01-19 | Cancer Therapeutics Crc Pty Limited | VEGFR3 inhibitors |
EP2887965A1 (en) | 2012-08-22 | 2015-07-01 | ImmunoGen, Inc. | Cytotoxic benzodiazepine derivatives |
ES2907763T3 (en) | 2012-08-31 | 2022-04-26 | Sutro Biopharma Inc | Modified amino acids comprising an azido group |
WO2014041349A1 (en) | 2012-09-12 | 2014-03-20 | Cancer Therapeutics Crc Pty Ltd | Tetrahydropyran-4-ylethylamino- or tetrahydropyranyl-4-ethyloxy-pyrimidines or -pyridazines as isoprenylcysteincarboxymethyl transferase inhibitors |
WO2014045101A1 (en) | 2012-09-21 | 2014-03-27 | Cellzome Gmbh | Tetrazolo quinoxaline derivatives as tankyrase inhibitors |
US9394257B2 (en) | 2012-10-16 | 2016-07-19 | Tolero Pharmaceuticals, Inc. | PKM2 modulators and methods for their use |
US9260426B2 (en) | 2012-12-14 | 2016-02-16 | Arrien Pharmaceuticals Llc | Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors |
CN104755463A (en) | 2012-12-21 | 2015-07-01 | 卫材R&D管理有限公司 | Amorphous form of quinoline derivative, and method for producing same |
JP6423804B2 (en) | 2013-02-28 | 2018-11-14 | イミュノジェン・インコーポレーテッド | Complex containing cell binding agent and cytotoxic agent |
JP6494533B2 (en) | 2013-02-28 | 2019-04-03 | イミュノジェン・インコーポレーテッド | Complexes comprising maytansinoids as cell binding agents and cytotoxic agents |
CN105408320B (en) * | 2013-03-13 | 2019-08-13 | 北京强新生物科技有限公司 | 3- (aryl or heteroaryl) methyl indol -2- ketone derivatives as cancer stem cell approach kinase inhibitor for treating cancer |
AU2014236455B2 (en) | 2013-03-14 | 2018-07-12 | Forsight Vision4, Inc. | Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant |
US10202356B2 (en) | 2013-03-14 | 2019-02-12 | Tolero Pharmaceuticals, Inc. | JAK2 and ALK2 inhibitors and methods for their use |
AR095443A1 (en) | 2013-03-15 | 2015-10-14 | Fundación Centro Nac De Investig Oncológicas Carlos Iii | HEREROCICLES CONDENSED WITH ACTION ON ATR |
US9206188B2 (en) | 2013-04-18 | 2015-12-08 | Arrien Pharmaceuticals Llc | Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors |
CN104119321B (en) * | 2013-04-28 | 2017-09-08 | 齐鲁制药有限公司 | The 2-maleate and its polymorph of indolinone derivative |
MX368099B (en) | 2013-05-14 | 2019-09-19 | Eisai R&D Man Co Ltd | Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds. |
WO2014194030A2 (en) | 2013-05-31 | 2014-12-04 | Immunogen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
ES2658039T3 (en) | 2013-07-10 | 2018-03-08 | Sutro Biopharma, Inc. | Antibodies comprising multiple site-specific non-natural amino acid residues, methods for their preparation and methods of use |
FR3008411B1 (en) * | 2013-07-12 | 2015-07-03 | Servier Lab | NOVEL 3 - [(3 - {[4- (4-MORPHOLINYLMETHYL) -1H-PYRROL-2-YL] METHYLENE} -2-OXO-2,3-DIHYDRO-1H-INDOL-5-YL) METHYL SALT ] -1,3-THIAZOLIDINE-2,4-DIONE, ITS PREPARATION, AND THE FORMULATIONS CONTAINING IT |
ES2813877T3 (en) | 2013-08-28 | 2021-03-25 | Crown Bioscience Inc Taicang | Gene expression flags predictive of a subject's response to a multikinase inhibitor and methods of using the same |
WO2015054658A1 (en) | 2013-10-11 | 2015-04-16 | Sutro Biopharma, Inc. | Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use |
US9278955B2 (en) | 2013-10-18 | 2016-03-08 | Sun Pharmaceutical Industries Limited | Ascorbic acid salt of sunitinib |
US9604968B2 (en) | 2013-10-18 | 2017-03-28 | Sun Pharmaceutical Industries Limited | Pure crystalline Form II of L-malic acid salt of sunitinib and processes for its preparation |
BR112016008806A2 (en) | 2013-11-01 | 2017-10-03 | Pfizer | VECTORS FOR EXPRESSION OF PROSTATE-ASSOCIATED ANTIGENS |
JP2016539149A (en) | 2013-12-06 | 2016-12-15 | ノバルティス アーゲー | Alpha-isoform selective phosphatidylinositol 3-kinase inhibitor dosing regimen |
CN104829596B (en) | 2014-02-10 | 2017-02-01 | 石家庄以岭药业股份有限公司 | Pyrrole-substituted indolinone derivative and preparation method thereof, composition including derivative, and application of derivative |
CN103923014A (en) * | 2014-05-05 | 2014-07-16 | 宁夏宝马药业有限公司 | Preparation method of cyclocreatine |
MY182793A (en) | 2014-08-08 | 2021-02-05 | Forsight Vision4 Inc | Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof |
JO3783B1 (en) | 2014-08-28 | 2021-01-31 | Eisai R&D Man Co Ltd | Highly pure quinoline derivative and method for producing the same |
TWI595006B (en) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | Anti-pd-1 antibodies and methods of use thereof |
WO2016114322A1 (en) | 2015-01-13 | 2016-07-21 | 国立大学法人京都大学 | Agent for preventing and/or treating amyotrophic lateral sclerosis |
DK3263106T3 (en) | 2015-02-25 | 2024-01-08 | Eisai R&D Man Co Ltd | PROCESS FOR SUPPRESSING BITTERNESS OF QUINOLINE DERIVATIVES |
CA2978226A1 (en) | 2015-03-04 | 2016-09-09 | Merck Sharpe & Dohme Corp. | Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer |
MX2017013383A (en) | 2015-04-20 | 2017-12-07 | Tolero Pharmaceuticals Inc | Predicting response to alvocidib by mitochondrial profiling. |
WO2016184793A1 (en) | 2015-05-15 | 2016-11-24 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for treating a patient with vegfr inhibitor-resistant metastatic renal cell carcinoma |
KR102608921B1 (en) | 2015-05-18 | 2023-12-01 | 스미토모 파마 온콜로지, 인크. | Albocidip prodrug with increased bioavailability |
GB201510019D0 (en) | 2015-06-09 | 2015-07-22 | Cancer Therapeutics Crc Pty Ltd | Compounds |
CN107801379B (en) | 2015-06-16 | 2021-05-25 | 卫材R&D管理有限公司 | Anticancer agent |
MX2018001289A (en) | 2015-08-03 | 2018-04-30 | Tolero Pharmaceuticals Inc | Combination therapies for treatment of cancer. |
KR20180058758A (en) | 2015-09-22 | 2018-06-01 | 그레이버그 비젼, 인크. | Compounds and compositions for the treatment of ocular disorders |
GB2543550A (en) | 2015-10-21 | 2017-04-26 | Hox Therapeutics Ltd | Peptides |
AU2016347881A1 (en) | 2015-11-02 | 2018-05-10 | Novartis Ag | Dosage regimen for a phosphatidylinositol 3-kinase inhibitor |
EA038755B1 (en) | 2015-11-12 | 2021-10-14 | Грейбаг Вижн, Инк. | Aggregating microparticles for providing sustained release of a therapeuic agent for intraocular delivery |
KR20180104106A (en) | 2016-01-27 | 2018-09-19 | 서트로 바이오파마, 인크. | an anti-CD74 antibody conjugate, a composition comprising an anti-CD74 antibody conjugate, and an anti-CD74 antibody conjugate |
CN109072241A (en) | 2016-02-08 | 2018-12-21 | 维特里萨医疗公司 | With the improved composition of vitreous half-life and application thereof |
EP3228630A1 (en) | 2016-04-07 | 2017-10-11 | IMBA-Institut für Molekulare Biotechnologie GmbH | Combination of an apelin antagonist and an angiogenesis inhibitor for the treatment of cancer |
CN107459519A (en) | 2016-06-06 | 2017-12-12 | 上海艾力斯医药科技有限公司 | Annelated pyrimidines piperidines ring derivatives and its preparation method and application |
WO2018045379A1 (en) | 2016-09-02 | 2018-03-08 | Dana-Farber Cancer Institute, Inc. | Composition and methods of treating b cell disorders |
WO2018060833A1 (en) | 2016-09-27 | 2018-04-05 | Novartis Ag | Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib |
SG11201903483VA (en) | 2016-10-28 | 2019-05-30 | Icahn School Med Mount Sinai | Compositions and methods for treating ezh2-mediated cancer |
US11279694B2 (en) | 2016-11-18 | 2022-03-22 | Sumitomo Dainippon Pharma Oncology, Inc. | Alvocidib prodrugs and their use as protein kinase inhibitors |
US10786502B2 (en) | 2016-12-05 | 2020-09-29 | Apros Therapeutics, Inc. | Substituted pyrimidines containing acidic groups as TLR7 modulators |
EP3548478B1 (en) | 2016-12-05 | 2021-11-17 | Apros Therapeutics, Inc. | Pyrimidine compounds containing acidic groups |
WO2018106870A1 (en) | 2016-12-08 | 2018-06-14 | Icahn School Of Medicine At Mount Sinai | Compositions and methods for treating cdk4/6-mediated cancer |
US10132797B2 (en) | 2016-12-19 | 2018-11-20 | Tolero Pharmaceuticals, Inc. | Profiling peptides and methods for sensitivity profiling |
CN106916143B (en) * | 2017-03-14 | 2019-09-27 | 哈尔滨医科大学 | It is a kind of prevent and treat coronary heart disease drug and its application |
AU2018240462C1 (en) | 2017-03-23 | 2022-12-08 | Graybug Vision, Inc. | Drugs and compositions for the treatment of ocular disorders |
CN111201040A (en) | 2017-05-10 | 2020-05-26 | 灰色视觉公司 | Sustained release microparticles and suspensions thereof for medical therapy |
WO2019023316A1 (en) | 2017-07-26 | 2019-01-31 | Sutro Biopharma, Inc. | Methods of using anti-cd74 antibodies and antibody conjugates in treatment of t-cell lymphoma |
WO2019055579A1 (en) | 2017-09-12 | 2019-03-21 | Tolero Pharmaceuticals, Inc. | Treatment regimen for cancers that are insensitive to bcl-2 inhibitors using the mcl-1 inhibitor alvocidib |
US20200353076A1 (en) | 2017-09-18 | 2020-11-12 | Sutro Biopharma, Inc. | Anti-folate receptor alpha antibody conjugates and their uses |
US20200237766A1 (en) | 2017-10-13 | 2020-07-30 | Tolero Pharmaceuticals, Inc. | Pkm2 activators in combination with reactive oxygen species for treatment of cancer |
NL2019801B1 (en) | 2017-10-25 | 2019-05-02 | Univ Leiden | Delivery vectors |
US11472799B2 (en) | 2018-03-06 | 2022-10-18 | Icahn School Of Medicine At Mount Sinai | Serine threonine kinase (AKT) degradation / disruption compounds and methods of use |
EP3539536A1 (en) | 2018-03-15 | 2019-09-18 | MH10 Spolka z ograniczona odpowiedzialnoscia | A pharmaceutical composition of sunitinib or its salt thereof in its polymorphic form i |
JP7351859B2 (en) | 2018-06-04 | 2023-09-27 | アプロス セラピューティクス, インコーポレイテッド | Pyrimidine compounds containing acidic groups useful for treating diseases related to TLR7 regulation |
GB201810092D0 (en) | 2018-06-20 | 2018-08-08 | Ctxt Pty Ltd | Compounds |
GB201810581D0 (en) | 2018-06-28 | 2018-08-15 | Ctxt Pty Ltd | Compounds |
CA3103995A1 (en) | 2018-07-26 | 2020-01-30 | Sumitomo Dainippon Pharma Oncology, Inc. | Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same |
US20220047716A1 (en) | 2018-09-17 | 2022-02-17 | Sutro Biopharma, Inc. | Combination therapies with anti-folate receptor antibody conjugates |
MX2021006544A (en) | 2018-12-04 | 2021-07-07 | Sumitomo Pharma Oncology Inc | Cdk9 inhibitors and polymorphs thereof for use as agents for treatment of cancer. |
BR112021011894A2 (en) | 2018-12-21 | 2021-09-08 | Daiichi Sankyo Company, Limited | PHARMACEUTICAL COMPOSITION |
EP3924351A4 (en) | 2019-02-12 | 2022-12-21 | Sumitomo Pharma Oncology, Inc. | Formulations comprising heterocyclic protein kinase inhibitors |
WO2020191326A1 (en) | 2019-03-20 | 2020-09-24 | Sumitomo Dainippon Pharma Oncology, Inc. | Treatment of acute myeloid leukemia (aml) with venetoclax failure |
AU2020242287A1 (en) | 2019-03-21 | 2021-09-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A Dbait molecule in combination with kinase inhibitor for the treatment of cancer |
AU2020245437A1 (en) | 2019-03-22 | 2021-09-30 | Sumitomo Pharma Oncology, Inc. | Compositions comprising PKM2 modulators and methods of treatment using the same |
EP3958845A1 (en) | 2019-04-25 | 2022-03-02 | Synthon B.V. | Pharmaceutical composition comprising amorphous sunitinib |
EP3962951A1 (en) | 2019-05-03 | 2022-03-09 | Sutro Biopharma, Inc. | Anti-bcma antibody conjugates |
CN114423463A (en) | 2019-05-06 | 2022-04-29 | 西奈山伊坎医学院 | Heterobifunctional compounds as HPK1 degradants |
EP4023639A1 (en) | 2019-08-31 | 2022-07-06 | Etern Biopharma (Shanghai) Co., Ltd. | Pyrazole derivative for fgfr inhibitor and preparation method therefor |
US20220401436A1 (en) | 2019-11-08 | 2022-12-22 | INSERM (Institute National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
EP4114852A1 (en) | 2020-03-03 | 2023-01-11 | Sutro Biopharma, Inc. | Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use |
CN111233841A (en) * | 2020-03-17 | 2020-06-05 | 湖北扬信医药科技有限公司 | Sunitinib related substance and preparation method and application thereof |
WO2023278424A1 (en) * | 2021-06-28 | 2023-01-05 | The Regents Of The University Of California | Methods for treating and ameliorating t cell related diseases |
CN113717159A (en) * | 2021-09-16 | 2021-11-30 | 中国药科大学 | Indolone compounds and pharmaceutical composition, preparation method and application thereof |
WO2023081923A1 (en) | 2021-11-08 | 2023-05-11 | Frequency Therapeutics, Inc. | Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof |
WO2023228095A1 (en) | 2022-05-24 | 2023-11-30 | Daiichi Sankyo Company, Limited | Dosage regimen of an anti-cdh6 antibody-drug conjugate |
US20240058465A1 (en) | 2022-06-30 | 2024-02-22 | Sutro Biopharma, Inc. | Anti-ror1 antibody conjugates, compositions comprising anti ror1 antibody conjugates, and methods of making and using anti-ror1 antibody conjugates |
WO2024017372A1 (en) * | 2022-07-22 | 2024-01-25 | 成都百裕制药股份有限公司 | Indolone derivative and use thereof |
Family Cites Families (101)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL104796C (en) | 1957-08-19 | |||
DE878539C (en) | 1939-08-17 | 1953-06-05 | Hoechst Ag | Process for the production of methine dyes |
BE507136A (en) | 1950-11-18 | |||
BE553661A (en) | 1955-12-23 | |||
NL96047C (en) | 1956-06-08 | |||
NL251055A (en) | 1959-04-29 | |||
FR1398224A (en) | 1964-05-06 | 1965-05-07 | Ici Ltd | Process for dyeing polyacrylonitrile textile materials |
US3308134A (en) | 1965-10-22 | 1967-03-07 | Mcneilab Inc | Spiro(indan-2, 3'-indoline)-1, 2'-diones |
US3551571A (en) | 1967-05-19 | 1970-12-29 | Endo Lab | Methods for reducing pain,reducing fever and alleviating inflammatory syndromes with heteroaromatic pyrrol-3-yl ketones |
US3564016A (en) | 1968-03-07 | 1971-02-16 | Endo Lab | Method of decarbonylation |
US4070366A (en) | 1968-06-12 | 1978-01-24 | Canadian Patents & Development Limited | Alkylation process |
FR1599772A (en) | 1968-09-17 | 1970-07-20 | ||
US3922163A (en) | 1970-01-30 | 1975-11-25 | Upjohn Co | Organic compounds and process |
US3715364A (en) | 1970-12-28 | 1973-02-06 | Merck & Co Inc | Nitroimidazole carboxamides |
DE2159363A1 (en) | 1971-11-30 | 1973-06-14 | Bayer Ag | Antimicrobial nitrofurans - useful eg as feed additives |
DE2159362A1 (en) | 1971-11-30 | 1973-06-14 | Bayer Ag | Amino-3-(5-nitro-2-furfurylidene)oxindoles - with antibacterial and antimycotic activity |
DE2159360A1 (en) | 1971-11-30 | 1973-06-14 | Bayer Ag | Acylamino-3-(5-nitro-2-furfurylidene) oxindoles - with antibacterial and antimycotic activity |
DE2159361A1 (en) | 1971-11-30 | 1973-06-14 | Bayer Ag | Diacylamino-3-(5-nitro-2-furfurylidene) oxindoles - - with antibacterial and antimycotic activity |
GB1384599A (en) | 1972-05-04 | 1975-02-19 | Colgate Palmolive Co | Coloured detergent compositions |
US3880871A (en) | 1973-09-27 | 1975-04-29 | Squibb & Sons Inc | Isothiocyanophenyl substituted imidazoles |
US4002643A (en) | 1975-06-27 | 1977-01-11 | Mcneil Laboratories, Inc. | Preparation of β-acyl pyrroles |
US4002749A (en) | 1975-08-12 | 1977-01-11 | E. R. Squibb & Sons, Inc. | Substituted indolinones |
US4053613A (en) | 1975-09-17 | 1977-10-11 | E. R. Squibb & Sons, Inc. | 1,3,thiazolinyl and 1,3 thiazinyl substituted indolinones |
DE2855306A1 (en) | 1978-12-21 | 1980-07-10 | Boehringer Sohn Ingelheim | HEART RATE REDUCTION AGENT |
GR73560B (en) | 1979-02-24 | 1984-03-15 | Pfizer | |
US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
US4343923A (en) | 1980-08-07 | 1982-08-10 | Armstrong World Industries, Inc. | Process for reducing the acid dye uptake of polyamide textile materials with N-acylimidazole compound |
CH646956A5 (en) | 1981-12-15 | 1984-12-28 | Ciba Geigy Ag | Imidazolides. |
EP0095285A1 (en) | 1982-05-21 | 1983-11-30 | Sumitomo Chemical Company, Limited | N-acylimidazoles, their production and use |
US4493642A (en) | 1982-12-27 | 1985-01-15 | Bogdon Glendon J | Orthodontic device and associated orthodontic method |
DE3310891A1 (en) | 1983-03-25 | 1984-09-27 | Boehringer Mannheim Gmbh, 6800 Mannheim | NEW INDOLINON (2) DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS AND INTERMEDIATE PRODUCTS |
US4489089A (en) | 1983-04-06 | 1984-12-18 | American Cyanamid Company | Substituted N-[ω-(1H-imidazol-1-yl)alkyl]-amides |
EP0124482B1 (en) | 1983-04-29 | 1989-11-08 | Ciba-Geigy Ag | Imidazolides and their use as curing agents for polyepoxides |
DE3415138A1 (en) | 1984-04-21 | 1985-10-31 | Basf Ag, 6700 Ludwigshafen | N- (AZOLYLCARBAMOYL) HYDROXYLAMINE AND FUNGICIDES CONTAINING THEM |
DE3426419A1 (en) | 1984-07-18 | 1986-01-23 | Boehringer Mannheim Gmbh, 6800 Mannheim | NEW OXINDOL DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS, AND INTERMEDIATE PRODUCTS |
US4560700A (en) | 1985-02-08 | 1985-12-24 | Merrell Dow Pharmaceuticals Inc. | Pyrrole-3-carboxylate cardiotonic agents |
JPH078851B2 (en) | 1985-07-29 | 1995-02-01 | 鐘淵化学工業株式会社 | 3-phenylthiomethylstyrene derivative |
US4966849A (en) | 1985-09-20 | 1990-10-30 | President And Fellows Of Harvard College | CDNA and genes for human angiogenin (angiogenesis factor) and methods of expression |
WO1993012786A1 (en) | 1986-07-10 | 1993-07-08 | Howard Harry R Jr | Indolinone derivatives |
US4853404A (en) | 1986-10-13 | 1989-08-01 | Tanabe Seiyaku Co., Ltd. | Phenoxyacetic acid derivatives composition and use |
US5089516A (en) | 1987-03-11 | 1992-02-18 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | 1-phenyl-3,5-pyrazolidinedione hydroxystyrene compounds which have tyrosine kinase inhibiting activity |
EP0304493B1 (en) | 1987-03-11 | 1992-09-02 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | Hydroxystyrene derivatives |
US5202341A (en) | 1987-03-11 | 1993-04-13 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | Hydroxystyrene compounds having tyrosine kinase inhibiting activity |
US5043348A (en) | 1987-04-24 | 1991-08-27 | Cassella Aktiengesellschaft | Pyrrolealdehydes, their preparation and their use |
US5217999A (en) | 1987-12-24 | 1993-06-08 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Styryl compounds which inhibit EGF receptor protein tyrosine kinase |
DE3808071A1 (en) | 1988-03-11 | 1989-09-21 | Basf Ag | METHOD FOR PRODUCING ACYLATED IMIDAZOLES |
US4868304A (en) | 1988-05-27 | 1989-09-19 | Iowa State University Research Foundation, Inc. | Synthesis of nitrogen heterocycles |
CA1339784C (en) | 1988-06-23 | 1998-03-31 | Shinya Inoue | Pyrrolecarboxylic acid derivatives |
JPH06104658B2 (en) | 1988-06-23 | 1994-12-21 | 三菱化成株式会社 | Pyrrolecarboxylic acid derivative |
GB8816944D0 (en) | 1988-07-15 | 1988-08-17 | Sobio Lab | Compounds |
DE3824658A1 (en) | 1988-07-15 | 1990-01-18 | Schering Ag | N-HETARYL IMIDAZOLE DERIVATIVES |
US5084280A (en) | 1988-12-15 | 1992-01-28 | Chapman Chemical Company | Wood preservation composition and method |
DE3902439A1 (en) | 1989-01-27 | 1990-08-02 | Basf Ag | PLANT PROTECTIVE AGENTS BASED ON 1-ARYL OR 1-HETARYLIMIDAZOLE CARBONIC ACID ESTERS |
US5047554A (en) | 1989-04-18 | 1991-09-10 | Pfizer Inc. | 3-substituted-2-oxindole derivatives |
EP0429685B1 (en) | 1989-07-25 | 1997-10-29 | Taiho Pharmaceutical Company, Limited | Oxoindole derivative |
US5258357A (en) | 1989-10-07 | 1993-11-02 | Basf Aktiengesellschaft | Carboxamides, their preparation and their use as herbicides |
CA2032421A1 (en) | 1989-12-20 | 1991-06-21 | Mitsubishi Chemical Corporation | Pyrrolealdehyde derivative |
GB9004483D0 (en) | 1990-02-28 | 1990-04-25 | Erba Carlo Spa | New aryl-and heteroarylethenylene derivatives and process for their preparation |
CA2012634A1 (en) | 1990-03-20 | 1991-09-20 | Hassan Salari | Tyrphostins for treatment of allergic, inflammatory and cardiovascular diseases |
US5302606A (en) | 1990-04-16 | 1994-04-12 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase |
US5196446A (en) | 1990-04-16 | 1993-03-23 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Certain indole compounds which inhibit EGF receptor tyrosine kinase |
IT1247509B (en) | 1991-04-19 | 1994-12-17 | Univ Cagliari | SYNTHESIS COMPOUNDS FOR USE IN THE TREATMENT OF RHINOVIRUS INFECTIONS |
US5480883A (en) | 1991-05-10 | 1996-01-02 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
SG64322A1 (en) | 1991-05-10 | 1999-04-27 | Rhone Poulenc Rorer Int | Bis mono and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase |
GB9115160D0 (en) | 1991-07-12 | 1991-08-28 | Erba Carlo Spa | Methylen-oxindole derivatives and process for their preparation |
US5124347A (en) | 1991-07-31 | 1992-06-23 | Warner-Lambert Co. | 3-5-ditertiarybutylphenyl-4-hydroxymethylidene derivatives of 1,3-dihydro-2H-indole-2-ones as antiinflammatory agents |
HU219131B (en) | 1991-10-18 | 2001-02-28 | Monsanto Co. | Method and fungicidal composition for the control of take-all disease of plants and the active ingredients |
US5322950A (en) | 1991-12-05 | 1994-06-21 | Warner-Lambert Company | Imidazole with angiotensin II antagonist properties |
US5389661A (en) | 1991-12-05 | 1995-02-14 | Warner-Lambert Company | Imidazole and 1,2,4-triazole derivatives with angiotensin II antagonist properties |
AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
FR2689397A1 (en) | 1992-04-01 | 1993-10-08 | Adir | Use of di:tert-butyl-4-hydroxy-benzylidenyl-indoline-2-one - as an antioxidant, prostanoid synthesis inhibitor and platelet anti aggregant to treat atheroma, arteriosclerosis inflammatory diseases, etc. |
DE4211531A1 (en) | 1992-04-06 | 1993-10-07 | Cassella Ag | Process for the preparation of pyrrole derivatives |
FR2694004B1 (en) | 1992-07-21 | 1994-08-26 | Adir | News 3- (Hydroxybenzylidenyl) -indoline-2-ones and 3- (hydroxybenzylidenyl) -indoline-2-thiones, methods of preparation, and pharmaceutical compositions containing them. |
US5565324A (en) | 1992-10-01 | 1996-10-15 | The Trustees Of Columbia University In The City Of New York | Complex combinatorial chemical libraries encoded with tags |
US5330992A (en) | 1992-10-23 | 1994-07-19 | Sterling Winthrop Inc. | 1-cyclopropyl-4-pyridyl-quinolinones |
GB9226855D0 (en) | 1992-12-23 | 1993-02-17 | Erba Carlo Spa | Vinylene-azaindole derivatives and process for their preparation |
JP3507124B2 (en) | 1993-05-26 | 2004-03-15 | 塩野義製薬株式会社 | Method for producing benzylidene derivative |
EP0632102B1 (en) | 1993-06-28 | 1997-04-02 | Bayer Ag | Mass dyeing of synthetic material |
US5332736A (en) | 1993-11-01 | 1994-07-26 | Ortho Pharmaceutical Corporation | Anti-convulsant aroyl aminoacylpyrroles |
US5610173A (en) | 1994-01-07 | 1997-03-11 | Sugen, Inc. | Formulations for lipophilic compounds |
GB9507298D0 (en) | 1995-04-07 | 1995-05-31 | Pharmacia Spa | Substituted indolylmethylene-oxindale analogues as tyrosine kinase inhibitors |
US5786488A (en) | 1996-11-13 | 1998-07-28 | Sugen, Inc. | Synthetic methods for the preparation of indolyquinones |
US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
JP3246712B2 (en) | 1995-11-15 | 2002-01-15 | 株式会社トクヤマ | Method for producing ethenylamide compound |
EP0788890A1 (en) | 1996-02-06 | 1997-08-13 | Agfa-Gevaert N.V. | Dyes and dye-donor elements for thermal dye transfer recording |
CA2206201A1 (en) | 1996-05-29 | 1997-11-29 | Yoshiaki Isobe | Pyrazole derivatives and their pharmaceutical use |
ATE255090T1 (en) | 1996-08-01 | 2003-12-15 | Merckle Gmbh | ACYLPYRROLDICARBONONIC ACIDS AND ACYLINDOLICARBONONIC ACIDS AND THEIR DERIVATIVES AS INHIBITORS OF CYTOSOLIC PHOSPHOLIPASE A2 |
CA2289102A1 (en) * | 1997-05-07 | 1998-11-12 | Sugen, Inc. | 2-indolinone derivatives as modulators of protein kinase activity |
US6133305A (en) | 1997-09-26 | 2000-10-17 | Sugen, Inc. | 3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity |
HUP0103617A2 (en) * | 1998-05-29 | 2002-02-28 | Sugen, Inc. | Pyrrole substituted 2-indolinone protein kinase inhibitors, pharmaceutical compositions containing the compounds and their use |
US6462072B1 (en) | 1998-09-21 | 2002-10-08 | Gpi Nil Holdings, Inc. | Cyclic ester or amide derivatives |
JP2002542147A (en) | 1998-12-14 | 2002-12-10 | セレジィ ファーマシューティカルス, インコーポレイテッド | Compositions and methods for the treatment of anorectal disorders |
BR9916327A (en) * | 1998-12-17 | 2001-09-18 | Hoffmann La Roche | 4-alkenyl (and alkynyl) oxindols as inhibitors of cyclin-dependent kinases, in particular, cdk2 |
US6284894B1 (en) | 1998-12-18 | 2001-09-04 | Nycomed Imaging As | Preparation of allylic aromatic compounds |
AU760964B2 (en) * | 1998-12-31 | 2003-05-22 | Sugen, Inc. | 3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activityand for use in cancer chemotherapy |
WO2001037820A2 (en) * | 1999-11-24 | 2001-05-31 | Sugen, Inc. | Ionizable indolinone derivatives and their use as ptk ligands |
CA2395461C (en) * | 1999-12-22 | 2010-05-25 | Sugen, Inc. | Methods of modulating c-kit tyrosine kinase function with indolinone compounds |
CA2399358C (en) * | 2000-02-15 | 2006-03-21 | Sugen, Inc. | Pyrrole substituted 2-indolinone protein kinase inhibitors |
MY128450A (en) | 2000-05-24 | 2007-02-28 | Upjohn Co | 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives |
WO2002002551A1 (en) * | 2000-06-30 | 2002-01-10 | Sugen, Inc. | 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors |
JP2004518669A (en) * | 2000-12-20 | 2004-06-24 | スージェン・インコーポレーテッド | 4-Aryl substituted indolinone |
-
2001
- 2001-02-15 CA CA002399358A patent/CA2399358C/en not_active Expired - Lifetime
- 2001-02-15 IL IL15112701A patent/IL151127A0/en active Protection Beyond IP Right Term
- 2001-02-15 DE DE122008000002C patent/DE122008000002I1/en active Pending
- 2001-02-15 UA UA2002097427A patent/UA73976C2/en unknown
- 2001-02-15 DK DK01914376T patent/DK1255752T3/en active
- 2001-02-15 PL PL361209A patent/PL211834B1/en unknown
- 2001-02-15 WO PCT/US2001/004813 patent/WO2001060814A2/en active Application Filing
- 2001-02-15 ME MEP-2008-530A patent/ME00415B/en unknown
- 2001-02-15 ES ES01914376T patent/ES2290117T3/en not_active Expired - Lifetime
- 2001-02-15 SK SK1326-2002A patent/SK287142B6/en not_active IP Right Cessation
- 2001-02-15 PE PE2001000172A patent/PE20011083A1/en active IP Right Grant
- 2001-02-15 AR ARP010100703A patent/AR034118A1/en active IP Right Grant
- 2001-02-15 EP EP01914376A patent/EP1255752B1/en not_active Expired - Lifetime
- 2001-02-15 KR KR1020027010706A patent/KR100713960B1/en active IP Right Grant
- 2001-02-15 DE DE122010000004C patent/DE122010000004I1/en active Pending
- 2001-02-15 HU HU0204433A patent/HU228979B1/en active Protection Beyond IP Right Term
- 2001-02-15 DE DE60129794T patent/DE60129794T2/en not_active Expired - Lifetime
- 2001-02-15 NZ NZ520640A patent/NZ520640A/en not_active IP Right Cessation
- 2001-02-15 BR BRPI0117360A patent/BRPI0117360B8/en not_active IP Right Cessation
- 2001-02-15 JP JP2001560198A patent/JP3663382B2/en not_active Expired - Lifetime
- 2001-02-15 SI SI200130778T patent/SI1255752T1/en unknown
- 2001-02-15 EA EA200200862A patent/EA005996B1/en not_active IP Right Cessation
- 2001-02-15 PT PT01914376T patent/PT1255752E/en unknown
- 2001-02-15 MX MXPA02008021A patent/MXPA02008021A/en active IP Right Grant
- 2001-02-15 AU AU2001239770A patent/AU2001239770B2/en not_active Expired
- 2001-02-15 AU AU3977001A patent/AU3977001A/en active Pending
- 2001-02-15 AT AT01914376T patent/ATE369359T1/en active
- 2001-02-15 US US09/783,264 patent/US6573293B2/en not_active Expired - Lifetime
- 2001-02-15 CN CNB018072690A patent/CN1329390C/en not_active Expired - Lifetime
- 2001-02-15 BR BR0108394-5 patent/BRPI0108394B8/en not_active IP Right Cessation
- 2001-02-15 MY MYPI20010696A patent/MY130363A/en unknown
- 2001-02-15 CO CO01012068A patent/CO5280092A1/en not_active Application Discontinuation
- 2001-02-15 CZ CZ20023081A patent/CZ303705B6/en unknown
- 2001-02-15 RS YUP-614/02A patent/RS50444B/en unknown
- 2001-07-04 TW TW090103496A patent/TWI306860B/en not_active IP Right Cessation
-
2002
- 2002-08-13 IS IS6501A patent/IS2491B/en unknown
- 2002-08-13 NO NO20023831A patent/NO325532B1/en not_active IP Right Cessation
- 2002-09-10 BG BG107078A patent/BG65764B1/en unknown
- 2002-09-13 HR HR20020751A patent/HRP20020751B1/en not_active IP Right Cessation
-
2003
- 2003-04-14 US US10/412,690 patent/US20040063773A1/en not_active Abandoned
- 2003-05-12 HK HK03103304A patent/HK1051188A1/en not_active IP Right Cessation
-
2005
- 2005-01-04 US US11/028,477 patent/US7125905B2/en not_active Expired - Lifetime
-
2006
- 2006-09-06 US US11/517,529 patent/US7572924B2/en not_active Expired - Lifetime
-
2007
- 2007-09-13 CY CY20071101186T patent/CY1108032T1/en unknown
-
2008
- 2008-01-08 NL NL300332C patent/NL300332I2/en unknown
- 2008-01-09 LU LU91407C patent/LU91407I2/en unknown
- 2008-01-15 FR FR08C0002C patent/FR08C0002I2/en active Active
- 2008-02-04 LT LTPA2008002C patent/LTC1255752I2/en unknown
- 2008-02-08 CY CY200800004C patent/CY2008004I2/en unknown
- 2008-12-08 NO NO2008019C patent/NO2008019I2/en unknown
-
2009
- 2009-12-29 NL NL300430C patent/NL300430I2/en unknown
-
2010
- 2010-02-09 NO NO2010002C patent/NO2010002I2/en unknown
- 2010-02-11 BE BE2010C009C patent/BE2010C009I2/fr unknown
- 2010-03-03 LU LU91657C patent/LU91657I2/en unknown
- 2010-03-09 CY CY2010004C patent/CY2010004I1/en unknown
-
2012
- 2012-01-09 CR CR20120009A patent/CR20120009A/en unknown
- 2012-01-09 CR CR20120007A patent/CR20120007A/en unknown
-
2019
- 2019-02-05 NO NO2019005C patent/NO2019005I1/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BG107078A (en) | Pyrrole-substituted 2-indolinone protein kinase inhibitors | |
JP4580133B2 (en) | Method for producing rigid and flexible polyurethane foams containing flame retardants | |
US5006569A (en) | Density reduction in flexible polyurethane foams | |
KR102195493B1 (en) | Flame retardant polyurethane foam and method for producing same | |
EP1973965B1 (en) | Non-halogen flame retardant additives for use in rigid polyurethane foam | |
EP0548613B1 (en) | Process for the preparatiuon of polyurethane foams employing polyol dispersions containing polyisocyanate polyaddition solids | |
DE602004002308T2 (en) | Low acid content organometallic catalyst for the production of rigid, semi-rigid and rigid polyurethane foams | |
JPH02105811A (en) | Preparation of polyurethane foam | |
JPH0372650B2 (en) | ||
US5177046A (en) | Amine-boron adducts as reduced odor catalyst compositions for the production of polyurethanes | |
KR100582975B1 (en) | Composites Comprising a Hydrophilic Polyester-Polyurethane Foamed Material and a Process for the Production of Composite Materials for Vehicle Interior Trim | |
US8802746B2 (en) | Isocyanate-based foam having improved anti-yellowing properties and process for production thereof | |
US3637542A (en) | Urethane foams with reduced smoke levels | |
EP1858949B1 (en) | Flame retarded polyester polyurethane foam containing fumed silica | |
KR20070053708A (en) | Reactivity drift and catalyst degradation in polyurethane foam | |
CN1120192C (en) | Active methano-compound containing tertiary amine for improving stability of size of polyurethane | |
AU698051B2 (en) | Breathable open cell urethane polymers | |
JPH1087777A (en) | Production of highly fluid and expandable polyurethane preparation and expanded polyurethane molded product | |
US5086081A (en) | Amine-boron adducts as reduced odor catalyst compositions for the production of polyurethanes | |
WO1993003090A1 (en) | Flexible water-blown polyurethane foams | |
PL167084B1 (en) | Melamine preparation | |
BG712Y1 (en) | Polyurethane composition | |
US3639307A (en) | Urethane foams with reduced smoke levels | |
EP0394246B1 (en) | Rapid cure of polyurethane foam with ammonium containing materials | |
US5130403A (en) | Amine-boron adducts as reduced odor catalyst compositions for the production of polyurethanes |